DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
   1 
 NCI Protocol #:  Not Applicable 
 
DF/HCC Protocol #: 17-030 
 
TITLE:   A Phase I/II Study of LY3022855 with BRA F/MEK Inhibition in Patients with 
Melanoma  
 Coordinating Center:    Dana-Farber Cancer Institute 
 *Principal Investigator (PI):  Elizabeth Buchbinder MD 
 Melanoma Program 
 Dana-Farber Cancer Institute Elizabeth_Buchbinder@ DFCI.HARVARD.EDU 
    
 
Statistician:    Project Manager:  
Anita Giobbie-Hurder Adrienne Anderson RN, BSN 
Dana-Farber Cancer Institute Dana-Farber Cancer Institute  
Telephone: 617-632-2193 Telephone: 617-632-6594 
Fax: 617-632-2444 Fax: 617-632-5152 
agiohur@jimmy.harvard.edu Aanderson10@partners.org 
 
 
 
 
Agents:  
LY3022855 – Eli Lilly and Company 
Vemurafenib – Commercial Cobimetinib – Commercial 
 
IND #: 130,965 
 IND Sponsor:  Investigator-Initiated Study, Dr. Elizabeth Buchbinder MD  
 
 
Protocol Type / Version # / Version Date: Revision, Version #6, 31 July 2017 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
2 SUMMARY 	OF	CHANGES 	
	
DF/HCC	Protocol	#:	17‐030	
	
Protocol	Date:	31	July	2017	
	
#	Section(s) 	 Change(s) 	
1.	TOC;	Table	5;	Section	2.5.1	Explanation	of	rationale	for	flat	dosing	of	LY3022855;	
update	of	Table	5	to	include	n on‐weight	based	cohorts	for	
study	JSCA;	updated	Table	of	Contents	and	added	a	List	of	Figures.	Changes	per	FDA	reque st	for	further 	information.	
2.	1.3;	2.2.2;	2.3;	2.4;	
2.5.1;	2.5.2;	3.1.8;	3.2.13;	5.1;	5.3.1;	5.4;	
5.5.2;	5.6;	5,8;	6.2;	6.3;	
7.1;	11.1;	13.1	Secondary	objective	for	the	ph ase	I	portion	of	the	trial	
further	defined	per	FDA	requ est;	Background	information	
on	LY3022855	edited	per	updated	IB;	Background	information	on	 vemurafenib and cobimetinib edited; Rationale 
for flat-dosing of LY3022855 edited;	Eligibility	criterion	3.1.8	
edited	to	include	additional	parameters	for	defining	
adequate	organ	function	per	FDA	request;	Strong	and	
moderate	CYP3A	inhibitors	were 	prohibited	for	all	portions	
of	the	trial	per	FDA	request;	Definition	of	the	RP2D	elaborated	to	include	consideration	of	toxicity	occurring	
outside	of	the	DLT	time	window	per	FDA	request,and	dose	
level	3	removed;	Hypersensitivit y	reaction	section	edited	to	
include	suggested	medication	intervention	per	FDA	request;	DLT	criteria	edited	to	include	Grade	4	anemia	and	to	
remove	allowance	of	Grade	3	A ST/ALT	increases	lasting	
fewer	than	8	days	per	FDA	req uest;	Modified	criteria	for	
taking	participants	off	therapy	to	reference	unacceptable	AEs	per	FDA	request;	Clarified	that	tumor	evaluations	
would	continue	on	schedule	in	the	event	of	dose	delays	as	
per	FDA	request;	Added	info rmation	that	LY3022855	must	
be	reduced	as	part	of	the	1
st	dose	reduction	for	a	toxicity	
and	further	clarified	that	patie nts	undergoing	intra‐patient	
dose	escalation	would	not	be	allowed	to	escalate	to	a	dose	level	beyond	the	MTD	per	FDA	request;	Added	specification	
that	vemurafenib	and	cobimetinib	may	be	reduced	per	FDA	
prescribing	information;	Edited	expected	toxicities	for	
clarity;	Edited	section	11	to	inc lude	definition	of	evaluable	
disease	for	phase	I	enrollment	purposes;	Edited	statistical	section	for	clarity	that	the	MTD	will	be	defined	in	a	
minimum	of	6	patients;	General	formatting	updates	to	
references	to	Tables/Sections	throughout	document.	
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
3 #	Section(s) 	 Change(s) 	
3.	Schema;	3.1.3;	5.1;	
5.3.1;	13	Schema	and	Section	5.1	edited	to	reflect	starting	dose	level	of	50	mg	for	LY3022855	and	removal	of	fallback	dose	level;	
Eligibility	criterion	3.1.3	edited	for	clarity;	Section	5.3.1	
hypersensitivity	reaction	guidelines	edited;	Section	13	
edited	to	reflect	change	in	prot ocol	sample	size	with	altered	
dose	levels.	
4.	2.5.2;	2.6;	3.1.7;	7.1;	12.1.2;	12.2;	Study	Calendar	Protocol	document	edited	to	comply	with	DFCI	departmental	review	comments.	
5.	 3.2.2	Clarification	of	washout	for	prior	BRAF/MEK	inhibitor	
therapy	(applicable	only	to	phase	I	participants).	
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  4 
 SCHEMA 
 
 Phase I Portion: 
 
 
  
 
 
 
 
 
 
   
 
 
 
Phase II Portion: 
  
 
 
  
  
 
 
 
 
 
 
  Yes No Enroll 
beginning 
with dose 
level 1 Treat cohort 
(3 participants 
per cohort, with 1 
cycle = 28 days) No further escalation. Recruit 3 more 
participants 
Further 
DLTs? 
Escalate dose 1 
Participant 
diagnosed with 
advanced melanoma 
that has been 
confirmed to harbor 
a BRAF V600E/K 
mutationInformed consent 
and confirmation of 
trial eligibility Number of 
DLTs 
No further escalation.  2 or 3 
0 
Informed consent and confirmation 
of trial eligibility 
 
Participant 
receives 2 cycles 
of treatment 
(where 1 cycle = 
28 da
ys)   Discontinue protocol 
therapy and complete end 
of study assessments Stable disease, 
partial, or 
complete 
response 
Disease 
Progression Tumor 
Assessment Participant diagnosed with 
advanced melanoma that has 
been confirmed to harbor a 
BRAF V600E/ K mutation Continue for another 2 cycles 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  5 
 TABLE OF CONTENTS 
 
SCHEMA ........................................................................................................................ .................4  
1.  OBJECTIVES .................................................................................................................... ..8 
1.1 Study Design ............................................................................................................8  
1.2 Primary Objectives ...................................................................................................8  
1.3 Secondary Objectives ...............................................................................................8  
1.4 Exploratory Objectives ............................................................................................8  
2.  BACKGROUND .................................................................................................................9  
2.1 Study Disease ...........................................................................................................9  
2.2 LY3022855 ..............................................................................................................9  
2.3 Vemurafenib ..........................................................................................................27  
2.4 Cobimetinib............................................................................................................27  
2.5 Rationale ................................................................................................................28  
2.6 Correlative Studies Background ............................................................................36  
3.  PARTICIPANT SELECTION ...........................................................................................37  
3.1 Eligibility Criteria ..................................................................................................37  
3.2 Exclusion Criteria ..................................................................................................39  
3.3 Inclusion of Women and Minorities ......................................................................40  
4.  REGISTRATION PROCEDURES ...................................................................................40  
4.1 General Guidelines for DF/HCC Institutions ........................................................41  
4.2 Registration Process for DF/HCC Institutions .......................................................41  
4.3 General Guidelines for Other Investigative Sites ..................................................41  
4.4 Registration Process for Ot her Investigative Sites .................................................41  
5.  TREATMENT PLAN ........................................................................................................41  
5.1 Treatment Regimen ................................................................................................41  
5.2 Pre-Treatment Criteria ...........................................................................................43  
5.3 Agent Administration .............................................................................................43  
5.4 Definition of Dose-Limiting Toxicity (DLT) ........................................................45  
5.5 General Concomitant Medication an d Supportive Care Guidelines ......................46  
5.6 Criteria for Taking a Particip ant Off Protocol Therapy .........................................47  
5.7 Duration of Follow Up ...........................................................................................48  
5.8 Criteria for Taking a Participant Off Study ...........................................................48  
6.  DOSING DELAYS/DOSE MODIFICATIONS................................................................49  
6.1 Specific Toxicity Management ..............................................................................49  
6.2 Treatment Delays ...................................................................................................53  
6.3 Dose Modifications ................................................................................................53  
6.4 Overdose management ...........................................................................................55  
7.  ADVERSE EVENTS:  LIST AND RE PORTING REQUIREMENTS ............................55  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
6 7.1 Expected Toxicities ................................................................................................55  
7.2 Adverse Event Characteristics ...............................................................................55  
7.3 Serious Adverse Events .........................................................................................56  
7.4 Expedited Adverse Event Reporting ......................................................................57  
7.5 Expedited Reporting to the Food and Drug Administration (FDA) ......................57  
7.6 Expedited Reporting to Hospital Risk Management .............................................57  
7.7 Routine Adverse Event Reporting .........................................................................57  
8.  PHARMACEUTICAL INFORMATION ..........................................................................57  
8.1 LY3022855 ............................................................................................................57  
8.2 Vemurafenib ..........................................................................................................61  
8.3 Cobimetinib............................................................................................................62  
9.  BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES ........................................64  
9.1 Collection of Archival Tissue ................................................................................64  
9.2 Exploratory Fresh Tumor Biopsies ........................................................................64  
9.3 Laboratory Correlative Studies ..............................................................................65  
10. STUDY CALENDAR .......................................................................................................65  
11. MEASUREMENT OF EFFECT........................................................................................70  
11.1 Antitumor Effect – Solid Tumors ..........................................................................70  
12. DATA REPORTING / REGULATORY REQUIREMENTS ...........................................77  
12.1 Data Reporting .......................................................................................................78  
12.2 Data Safety Monitoring ..........................................................................................78  
13. STATISTICAL CONSIDERATIONS...............................................................................78  
13.1 Study Design/Endpoints.........................................................................................78  
13.2 Sample Size, Accrual Rate and Study Duration ....................................................79  
13.3 Analysis of Primary and Secondary Endpoints .....................................................80  
13.4 Reporting and Exclusions ......................................................................................80  
14. PUBLICATION PLAN .....................................................................................................81  
15. REFERENCES ..................................................................................................................82  
16. APPENDIX A PERFORMANC E STATUS CRITERIA ..................................................85  
 
 
LIST OF TABLES 
 
Table 1: Single-Dose Pharmacokinetics of LY3022855 .............................................................. 11  
Table 2: Multi-Dose Pharmacokine tics in Cynomolgus Monkeys ............................................... 12  
Table 3: Single-Dose Toxicity and Toxicoki netics of LY3022855 in Cynomolgus Monkeys .... 14  
Table 4: Multi-Dose Toxicity and Toxicoki netics of LY3022855 in C ynomolgus Monkeys ...... 17  
Table 5: Lilly-Sponsored Clinical Studies .................................................................................... 19  
Table 6: Related TEAEs by Cohort for Study JSCA Occurring in ≥ 2 Patients (N = 29) ............ 25  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
7 Table 7: Related TEAEs by Cohort for Study JSCB Occurring in ≥ 2 Patients (Safety Population, 
N = 14) ....................................................................................................................... ................... 26  
Table 8: Summary of Non-compartmental PK Parameters Following IV Infusion of Weight-
Based and Non-Weight-Based of Dosing LY3022855 in Cancer Patients during Cycle 1 for 
Study JSCA .................................................................................................................... ............... 29  
Table 9: Study JSCA:  Summary of Serious Treatment-Emergent A dverse Events for Flat Doses
....................................................................................................................................................... 35  
Table 10: Phase I Dose Escalation Schedule ................................................................................ 41  
Table 11: Phase I Dose Escalation Decision Criteria ................................................................... 42  
Table 12: Management of Elevated AST/ALT ............................................................................. 49  
Table 13: Management of Neutropenia ........................................................................................ 49  
Table 14: Management of  Thrombocytopenia .............................................................................. 50  
Table 15: Management of Rash or Photosensitivity ..................................................................... 50  
Table 16: Management of QTc Increase  (Associated with Vemurafenib) ................................... 50  
Table 17: Management of Nausea ................................................................................................  51 
Table 18: Management of Vomiting ............................................................................................. 51 
Table 19: Management of Diarrhea ..............................................................................................  51 
Table 20: Management of Constipation ........................................................................................ 5 2 
Table 21: Management of Other Toxicity .................................................................................... 52  
Table 22: Dose Modifications .................................................................................................. ..... 54 
Table 23: Study Calendar....................................................................................................... ....... 67 
Table 24: Participants with Measurable Disease ( i.e., Target Disease) ........................................ 76  
Table 25: Participants with  Non-Measurable Disease (i.e. , Non-Target Disease) ....................... 76  
Table 26: Accrual Targets ..................................................................................................... ........ 80 
 
LIST OF FIGURES 
 
Figure 1: Mean concentration-versus-tim e profiles for LY3022855 following intravenous 
administration to patients with cancer on Day 1 (upper panel) and on Days 15 and 22 (lower 
panel) for Study JSCA. ........................................................................................................ ......... 32  
Figure 2: Individual observed clearance versus patient body weight (upper panel) and 
LY3022855 dose (lower panel) for Study JSCA. ......................................................................... 33  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
8  
1. OBJECTIVES 
 
1.1 Study Design 
 
This is an open-label phase I/II study looking at  the combination of colo ny-stimulating factor-1 
receptor (CSF-1R) inhibition using LY3022855 with BRAF/MEK inhibitor therapy using 
vemurafenib and cobimetinib. The BRAF and MEK inhibition will be maintained at standard dosing with the addition of the LY3022855 in a typical 3+3 trial design. Once the maximum 
tolerated dose (MTD) is reached and a recommended phase II dose (RP2D) is chosen, a single-arm phase II study in patients with BRAF mutant melanoma will move forward.   
 1.2 
Primary Objectives 
 
Phase I:   
 To determine the MTD and RP2D of  the combination of LY3022855 with 
vemurafenib and cobimetinib. 
 
Phase II:   
 To evaluate the progression-free surviv al (PFS) rate in patients with BRAF  V600E 
or V600K mutated melanoma. 
 
1.3 Secondary Objectives 
 
Phase I:  
 To evaluate the preliminary overall response rate (ORR) and PFS rate of LY3022855 with vemurafenib and cobimetinib in  patients with melanoma 
harboring BRAF  V600E or V600K mutations. 
 Phase II: 
 To evaluate the ORR of the combination of LY3022855 with vemurafenib and 
cobimetinib in patients with BRAF V600E or V600K mutated melanoma. 
 To evaluate the overall survival (OS) in patients with BRAF  V600E or V600K 
melanoma to the combination of LY3022855 with vemurafenib and cobimetinib. 
 To continue to evaluate the safety an d tolerability of LY3022855 in combination 
with vemurafenib and cobimetinib. 
 
 
1.4 
Exploratory Objectives 
 To investigate the effect of the comb ination of LY3022855 with vemurafenib and 
cobimetinib on mitogen-activated protei n kinase (MAPK) pa thway signaling and 
the immune tumor microenvironment vi a collection of blood, archival tumor 
tissue, and optional pre and on-treatmen t tissue biopsies obtained during both 
phases of the trial.  
 To investigate the relationship between the levels of tumor DNA in serially 
collected plasma samples and the obser ved clinical outcomes during both phases 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
9 of the trial. 
 
 
2. BACKGROUND 
 2.1 
Study Disease 
 
Melanoma is the most deadly form of skin cancer, with over 10,000 d eaths estimated in 20161. 
About 40 - 60% of cutaneous melanomas carry mutations in BRAF that lead to constitutive 
activation of downstream signa ling through the MAPK pathway. Approximately 90% of these 
mutations result in the substitution of glutamic acid for valine at codon 600 (BRAF V600E), 
however other activating mutations are known to occur (e.g., BRAF  V600K)2,3.  
 BRAF inhibitor therapy with vemu rafenib or dabrafenib has an improved overall survival in 
patients with BRAF mutations with an even larger eff ect observed when combined with MEK 
inhibition using trametinib or cobimetinib
2,4,5. The response rate to the combination is 64 - 68%; 
however, these responses are of  limited duration. The median PFS for combination BRAF/MEK 
inhibitor therapy is only 9.9 - 11.4 months.  Prog ression on therapy is tho ught to occur primarily 
due to the development of acquired resistan ce through reactivation of  the MAPK pathway4,5. 
  
2.2 
LY3022855 
 
CSF-1R is a receptor tyrosine kinase expre ssed on monocyte/macrophage and granulocyte cell 
lineages in normal as well as tumor cells6,7. When colony-stimulati ng factor-1 (CSF-1) or 
interleukin 34 (IL-34) binds to CSF-1R, the r eceptor is phosphorylate d, initiating downstream 
signaling events which result in the regulation of  proliferation, differentiation, survival and 
migration of monocytes/macrophages8-10.  
 In cancer, increased infilt ration of macrophage s within and surrounding the tumor mass 
correlates with increased tumor invasiveness, growth, and poor prognosis. In breast, prostate, 
ovarian, and cervical cancer, th ere is a correlation between  tumor-associated macrophages 
(TAMs) and poor prognosis
11-13. Clinical evidence of TAM participation in tumor growth is 
corroborated in animal models where CSF-1R/CSF-1 signaling is  inhibited or knocked out. Mice 
with null mutations in the CSF-1 gene have simi lar initiation rates of virally induced mammary 
tumors as normal mice, but the tumors do not pr ogress to advanced carcinoma stages and the 
number of metastases are greatly reduced14. In addition to the effects of CSF-1R on 
macrophages, there are numerous reports of CSF-1R expression on cancer cells. For example breast, ovarian, endometrial, and leukemia ce lls of myeloid origin  express CSF-1R and 
proliferate in response to CSF-1
6,15-18. Targeting CSF-1R has th e potential to limit cancer 
progression.  While CSF-1R levels are infrequently increa sed on tumor cells compared to analogous normal 
cells, increased CSF-1 ligand in sera of cancer patients is frequently observed and is associated with poor prognosis and severity of disease in multiple cancers
19,20. This suggests that circulating 
CSF-1 modulates the stroma (i .e., macrophages) that contribu te to tumor progression. For 
example, in breast cancer, CSF-1 expression correlated with increased leukocytic infiltration, 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
10 high tumor grade, and poor clinical outcome21. It is hypothesized that the CSF-1 produced by 
tumor cells suppresses dendritic cell maturation and recruits TA Ms that are immunosuppressive, 
thus promoting angiogenesis and tumor growth22. The association of high levels of CSF-1 with 
poor prognosis in cancer patients may be a cons equence of elevated CSF-1 production by tumor 
cells. Moreover, elevated CSF-1 levels in sera of cancer patients may be an indicator of 
individuals more likely to bene fit from anti-CSF-1R treatment. 
 A recombinant human immunoglobulin type G1  (IgG1) that targets human CSF-1R, LY3022855 
was originally identified from a screen of hybridoma candidates that were generated following 
immunization of MEDAREX HuMAb™ human immunoglobulin G (IgG)-transgenic mice with human CSF-1R expressing NIH-3T3 cells and so luble CSF-1R protein. The antibody comprises 
two identical gamma ( γ) heavy chains and tw o identical kappa (κ ) light chains. 
 Since LY3022855 does not inhibit murine CSF-1R, a recombinant rat IgG1 antibody specific for 
murine CSF-1R (designated as CS7) was develo ped and utilized as a surrogate antibody to 
evaluate the effects of targ eting CSF-1R on macrophages in murine models of cancer. 
LY3022855 and CS7 were shown to inhibit the bi nding of both CSF-1 and IL-34 to human and 
mouse CSF-1R, respectively. In addition, LY3022855 and CS7 inhibited the phosphorylation 
both of their respective CSF-1R as well as of downstream signaling molecules. The effects of CS7 were evaluated in several mouse tumor mode ls of cancer establishe d with both human and 
murine tumor cells. Using CS7 as a single agen t to target CSF-1R on macrophages effectively 
reduced tumor volume in three human xenograft br east cancer models and two syngeneic murine 
mammary cancer models. In line with the pot ential utility of LY 3022855 as a combination 
therapy, CS7 increased the antitumor effects of targeted agents such as trastuzumab, doxorubicin, paclitaxel, and docetax el in preclinical models. When  comparing the effect of CS7 
in a range of animal models, antitumor effi cacy correlated with CSF-1-secreting tumors, 
supporting the potential use of CSF-1 levels as a predictor of responsivene ss to therapy. 
 On the basis of the above non-clinical findings, LY3022855 was considered to  be a candidate for 
clinical development as a treatment for cancer. A phase I trial to eval uate the safety, MTD, 
pharmacokinetics (PK), antitumor activity, im munogenicity, and pharmacodynamics (PD) of 
LY3022855 is currently ongoing.  
2.2.1 
Non-Clinical Studies 
 2.2.1.1 
Pharmacokinetics 
 The pharmacokinetics (PKs) of LY3022855 were  characterized in mice after a single 
intraperitoneal injecti on of 20 mg/kg and in cynomolgus m onkeys after a single intravenous (IV) 
infusion at dose levels of 10, 40, and 140 mg/kg. Th e PKs of CS7 were evaluated in mice after a 
single intraperitoneal injection (20 mg/kg). CS7 was produced to validate the strategy of 
targeting CSF-1R in mouse cancer models because LY3022855 does not cross-react with mouse CSF-1R. The half-life (t
1/2) of LY3022855 in mice was 110.4 hours, approximately three-fold 
greater than that of CS7. However, in the IV single-dose cynomolgus monkey study, the t 1/2 of 
LY3022855 was greater than that observed in mice, ranging from 183.3 to 275.2 hours (group 
means). In the primate study, LY3022855 exposure was generally dose proportional. The group 
means volume of distribution (V d) in the primate study ranged from 60.8 to 63.6 mL/kg, 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
11 indicating that the distributi on of LY3022855 is limited to the vasculature. LY3022855 exposure 
was continuous throughout the duration of th e primate study and no sex differences were 
observed. In the repeat-dose toxicology study, the PK para meters for LY3022855 after the 
administration of the first dose were cons istent with the single-dose study (see Table 1 ). 
 
Table 1: Single-Dose Pharmacokinetics of LY3022855 
 
 
 In a repeat-dose monkey t oxicology study, LY3022855 was administered to cynomolgus 
monkeys IV once weekly over four weeks via a 15 minute infusion at four different dose levels: 
0 (control), 20, 60, and 180 mg/kg. The serum concentrations of LY3022855 were more 
sustained over the sampling period after the fourth  dose compared with the first dose, with mean 
concentrations at 168 hours post dose rangi ng from 23 to 43% of the maximum serum 
concentration (C
max); time to maximum serum concentration (T max) generally occurred by 1 hour 
post end of infusion. The group means t 1/2 after the fourth dose wa s between 158 and 470 hours 
among recovery animals. The group means V d for recovery animals was between 29.2 and 51.2 
mL/kg and indicated limited distribution beyond the vasculature. Exposure after the fourth dose 
was moderately higher than after the first dose , with accumulation ratios of approximately two 
for the area under the curve from time 0 to 168 hours (AUC 0-168hr ) and 1.5 for C max. The exposure 
parameters for the C max and AUC 0-168hr generally increased proportionally with the increase in 
dose level, and no notable sex differences were  apparent (Table 2). Anti-LY3022855 antibodies 
(anti-drug antibodies [ADA]) were detected in 12 of 30 animals that were evaluated after 
administration of LY3022855. The apparent concen tration of LY3022855 was reduced in two of 
the 12 animals compared with that of animals from the same dose group that were negative for 
ADA.  The concentration of CSF-1 increased in animals treated with LY3022855 in  a similar manner to 
that observed in the single-dose primate st udy. After the first administration of LY3022855, 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
12 CSF-1 serum concentrations increased quickly between 0.5 and 24 hours post infusion but then 
increased only slightly until 168 hours post infusion. CSF-1 concentrations were comparable 
among all treatment groups after the first and four th doses, suggesting that maximal increases in 
CSF-1 were achieved with the lowest dose leve l studied. The concentrations of CSF-1 were 
sustained during the study, as high levels we re still present prior to the fourth dose 
administration. After the fourth dose, concentra tions generally decrease d after approximately 504 
hours post infusion in the 20 mg/kg group and af ter approximately 672 hours post the end of 
infusion for the 60 mg/kg group. Exposure to CSF-1 was similar during the first and fourth doses, with no notable accumu lation or sex differences. 
 
Table 2: Multi-Dose Pharmacoki netics in Cynomolgus Monkeys  
 
 Metabolism and Disposition 
 
Formal studies to characterize the metabolis m and disposition of LY3022855 have not been 
conducted. As a monoclonal antibody, LY3022855 will be largely confined to the extracellular 
space, which is supported by data from numerous investigations and is consistent with the PK evaluation of LY3022855. No formal metabolism studies of LY3022855 have been performed 
because the catabolism of antibodies by mammalian systems is largely understood and formal studies of the metabolic degradation of these molecules are not warranted. 
 
Excretion 
 
Formal excretion studies of LY3022855 have not been conducted.  2.2.1.2 
Safety Pharmacology  and Toxicology 
 A standard non-clinical toxi cology program for advancement of a monoclonal antibody into 
clinical trials in oncology i ndications was conducted to assess  the safety and toxicity of 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
13 LY3022855. The non-clinical safety assessment of LY3022855 was conducte d in cynomolgus 
monkeys. This species was considered a releva nt model for the safety evaluation of LY3022855 
based on a preliminary cross-species evaluation of tissue/receptor bind ing and/or functional in 
vitro  pharmacological activity in  human and cynomolgus monkey test systems and in a 
subsequent comprehensive tissu e cross-reactivity study using fu ll panels of monkey and human 
tissues. The toxicology studies  conducted with LY3022855 include d exploratory single-dose 
toxicity and toxicokinetic (TK)  dose range-finding study and a pi votal four week repeat-dose 
Good Laboratory Practice toxicity, TK, and im munogenicity study with a six week recovery 
period.  
 Animals were administered LY3022855 by IV infusion, the intended clinical method of administration, using the dosing schedule (once weekly) in the planne d initial clinical 
investigations of LY3022855. The pivotal study included evaluations of relevant safety 
pharmacology parameters. Due to an anticipated effect of LY3022855 on circulating levels of the 
target ligand, CSF-1, the level of CSF-1 was also  measured in the study animals as a potential 
marker of the PD activity of the antibody. A thor ough assessment of peripheral blood and spleen 
mononuclear cell subsets and an immunohistochemical  analysis of CD68+ cells (cellular marker 
of monocytes/macrophages) in liver and spleen were  also included to determine the effects that 
blockade of the CSF-1R might  have on these endpoints. 
 
Tissue Cross-Reactivity 
 
A comprehensive tissue cross-reactivity study was conducted in cryosections of normal human 
and cynomolgus monkey tissues using a fluorescei n isothiocyanate (FITC)-labeled form of 
LY3022855, designated LY3022855-FIT C, applied to cryosections of normal human and 
cynomolgus monkey tissues at 2 concentrations (5 and 0.5 µg/mL).  
 
The tissue-binding and distribut ion profile of LY3022855-FITC st aining observed in the human 
and cynomolgus monkey tissue panels was generally consistent with reported sites of CSF-1R 
expression, and no important unexpe cted (i.e., off-target) bindi ng was observed. Staining with 
LY3022855-FITC was present in the cytoplasm, cy toplasmic granules, and membrane granules 
of mononuclear cells and cells of myeloid a nd mononuclear phagocytic lineage. In human 
peripheral blood smears, staining of monocytes  was observed. Additiona lly, staining of the 
cytoplasm and cytoplasmic granules of hematopoietic precursor cells was observed in one human bone marrow sample. In cynomolgus monkey kidney, cytoplasmic staining of glomerular tuft 
cells consistent with mesangial cells was presen t. In human placenta, staining of the cytoplasm, 
cytoplasmic granules, and membrane of tr ophoblastic epithelium was observed. Although CSF-
1R is expressed mainly by cells of myel oid and mononuclear pha gocytic lineage (e.g., 
macrophages, monocytes, and glomerular mesangial cells), expression has al so been reported in 
cells of neuroepithelial lineage, including trophoblasts
23-25. 
 
Single-Dose Toxicity 
 
Single-dose administration of LY3022855 at dose levels of 10, 40, and 140 mg/kg administered 
by IV infusion over a 15 minute period was we ll tolerated in cynomolgus monkeys (two 
monkeys per sex per group) during the 14 da y observation period. Sustained dose-proportional 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
14 exposure to LY3022855 was generally observed th roughout the 14 day observation period at all 
dose levels following administration, with no apparent sex differences. A relatively long t 1/2 was 
observed for LY3022855, ranging from approximately 183 to 275 hours. 
 The key toxicological findings  after a single administration of LY3022855 were elevations in 
serum transaminases (ALT and AST) and LDH on days 2, 7, and 15 following dosing. Elevations in ALT were generally minimal at  the lowest dose level (10 mg/kg), whereas 
generally minimal to moderate elevations were  observed in ALT at 40 and 140 mg/kg and in 
AST and LDH across all dose groups. The elevati ons in ALT, AST, and LDH observed on day 7 
generally declined towards baseline levels in most animals by the end of the observation period, 
suggesting reversibility of these effects. No histological change s in the liver were noted to 
correlate with the increases in ALT, AST, a nd LDH, nor were any changes noted in liver 
functional parameters (i.e., alkaline phosphatase, bilirubin, or coagulation). Based on the small 
magnitude of the elevations and the absence of histological or functional changes, the increases 
in ALT, AST, and LDH were not considered advers e. Similar elevations in serum enzyme levels 
have also been observed when treating with other pharmacological agents targeting CSF-1R
26,27. 
 No other adverse clinical signs or effect s on food consumption, body weight, hematology, or 
organ weights were associated with administration of LY3022855. 
 The no-observed-adverse-effect level (NOAEL) in this study was considered to be the highest 
dose tested, 140 mg/kg. This dose corresponded to a dosing day 1 mean serum concentration at 
168 hours (C
168hr) of 1097 μg/mL, mean C max of 4010 µg/mL, and mean AUC 0-168hr of 303127 
μg·hr/mL for males and females ( Table 3 ). 
 
Table 3: Single-Dose Toxicity and Toxico kinetics of LY3022855 in Cynomolgus Monkeys  
 
  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
15 Multi-Dose Toxicity  
 
In the pivotal repeat-dose toxicity, TK, and immunogenicity study of LY3022855, doses of 0 
(control), 20, 60, and 180 mg/kg/dose of LY3022855 were administered by IV infusion once weekly to cynomolgus monkeys (5 monkeys per sex per group) for four weeks, followed by a six week recovery period. Standard toxicological an d relevant safety pharmacology (cardiovascular, 
central nervous, and respiratory systems) endpoi nts were assessed. As in the single-dose study, 
circulating levels of CSF-1 were measured. A thorough assessment of peripheral blood and spleen mononuclear cell subsets and an immunohis tochemical analysis of CD68+ mononuclear 
cells in liver and spleen  were also conducted. 
 IV infusion of LY3022855 was generally well tolerated at all dose levels. Sustained dose-proportional to slightly-greater-than-dose-proportional increase s in exposure to LY3022855 were 
observed, and no sex differences in exposur e were apparent. Moderate accumulation 
(approximately two-fold) of LY3022855 occurred  after repeated administration. ADA were 
detected in 12 of 30 animals treated with LY 3022855 (six were positive after the first dose and 
an additional six were positive af ter the last dose). In two of th e animals with ADA after the last 
dose, the presence of ADA appeared to decrease the concentration of LY3022855, thus impacting the TK analysis. The ADA in the othe r animals did not appear to affect serum 
LY3022855 concentrations.  As noted in the single-dose e xploratory study, circulating concen trations of CSF-1 increased 
shortly after LY3022855 administration. CSF-1 was not  detected in any co ntrol animals. In 
contrast to LY3022855, the concentration of CSF- 1 did not vary with dose, as comparable 
maximum levels were reached in  all three dose groups. Toward the end of the recovery period, 
CSF-1 levels generally decreased in the 20 and 60 mg/kg dose groups, but remained elevated in 
the 180 mg/kg dose group.  The key toxicological findings attributed to LY3022855 administration in this study were 
periorbital swelling, increases in serum transaminases as noted in  the exploratory study, changes 
in leukocyte populations (monocytes, neutrophils, CD68+ mononuclear cells, natural killer [NK] 
cells), as well as target organ effects in the liver (Kupffer ce ll hypertrophy/hyperplasia), spleen 
(follicular hypertrophy/dendritic cell hyperpla sia), and bone marrow (hypercellularity). The 
immunomodulatory effects on leukocytes, Kupffe r cells, spleen, and bone marrow likely reflect 
an exaggerated pharmacological response to LY 3022855, possibly associated with elevations in 
circulating CSF-1 levels noted during the study.  
 Elevations in ALT after the la st dosing of LY3022855 were genera lly minimal in the lowest dose 
group (20 mg/kg) and minimal to moderate at  the 60 and 180 mg/kg dose groups. AST levels 
were minimally to moderately increased in all do se groups. ALT and AST returned to baseline in 
the 20 mg/kg group and trended toward baselin e in the 60 and 180 mg/kg groups during the 
recovery period, but remained increased in some individual animals compared with baseline. No 
histological changes in the liver  were noted to correlate with the transaminase increases, nor 
were any changes noted in liv er functional parameters (alk aline phosphatase, bilirubin, or 
coagulation). Based on the small ma gnitude of the elevations and the absence of histological or 
functional changes, the increases in ALT and AST were not considered adverse. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
16  
Increases in circulating white blood cells due to increases in neutrophils and monocytes were 
observed in both sexes at 60 and 180 mg/kg. Flow cytometry analysis of spleen and peripheral blood revealed increases in monocytes in sple en and blood at 60 and 180 mg/kg and reductions 
in splenic NK cells in all LY3022855 treated gr oups. Variability in NK cell numbers in the 
peripheral blood of animals in all dose groups (including control) precluded assigning a 
definitive relationship with LY3022855 treatment. These changes in white blood cell counts, in conjunction with minimal revers ible increases in serum globulin concentrations with a 
corresponding decrease in albumin  to globulin ratio, are consiste nt with the presence of an 
inflammatory response. However, no histopath ological evidence of inflammation was observed. 
The monocyte, neutrophil, and globulin changes were reversible by the end of the recovery 
period, while the splenic NK cell reductions were s till apparent in some animals. These changes 
were not considered adverse be cause of their small magnitude. 
 Anatomic pathology changes attr ibuted to the administration of LY3022855 at the end of the 
dosing period included increased spleen weights in females in all dose groups, which generally 
correlated with splenic follicu lar hypertrophy (males at 60 and 180 mg/kg; females at 20 and 180 
mg/kg), bone marrow hypercellularity (all fe male dose groups, 1 male at 60 mg/kg), bone 
marrow lymphoid aggregates (1 male, 1 female at 180 mg/kg), and Kupffer cell hypertrophy/hyperplasia (primarily minimal, a ll male dose groups, 1 female at 60 mg/kg). 
Immunohistochemical analyses confirmed the pres ence of increased size  or number of CD68+ 
Kupffer cells in the liver and in creased numbers of CD68+ mononuclear  cells in the spleen at all 
dose levels. The CD68+ cells in the spleen we re likely follicular dendritic cells. The 
immunohistochemical findings in liv er and spleen generally correla ted with the histopathological 
diagnoses of Kupffer cell hypertrophy/hyperplasi a and splenic follicular hypertrophy. Similar 
anatomic pathology findings in spleen, liver, a nd bone marrow were observe d after the recovery 
period. These changes were not considered adverse because of their small magnitude. 
 Slight to moderate periorbital swelling was observed primarily during the recovery phase in all 
LY3022855 treated groups (20, 60, and 180 mg/kg/dose). This clinical sign has been reported to 
occur in humans with another antibody to CSF-1 and may thus represent a delayed response to 
LY3022855 in the treated monkeys . Watery feces was observed only in the 60 mg/kg/dose 
animals, but is considered possibly related to  the administration of LY3022855. These clinical 
signs were not considered adverse based on their limited impact to the overall health of the animal. No adverse effects were noted in asse ssments of the central nervous (neurological 
behavioral examination), resp iratory (rate), or cardiovascul ar (heart rate, blood pressure, 
electrocardiogram) systems. In addition, no evid ence of an adverse r eaction or intolerance 
attributable to LY3022855 wa s apparent at the injection sites af ter IV infusion in the cynomolgus 
monkey repeat-dose to xicity studies. 
 Based on the absence of any definitive LY 3022855 related adverse findings, the NOAEL for 
LY3022855 administered via 15 minute IV infusion w eekly on four occasions was considered to 
be 180 mg/kg/dose. The dose corresp onded to a dosing day 22 mean C
max of 7985 µg/mL, C 168hr 
of 2945 µg/mL, and mean AUC 0-168hr of 711340 µg·hr/mL ( Table 4 ). 
  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
17  
Table 4: Multi-Dose Toxicity and Toxico kinetics of LY3022855 in Cynomolgus Monkeys 
 
 
2.2.1.3 Efficacy Pharmacology 
 A series of in vitro  studies determined the pharmacodynamic (PD) properties of LY3022855 
toward its target, CSF- 1R. LY3022855 bound in a dose-dependent manner to human CSF-1R 
and blocked CSF-1 and IL-34 binding in a soli d-phase ligand-blocking assay. In addition to 
blocking ligand-induced receptor phosphoryl ation, LY3022855 inhibited ligand-induced 
phosphorylation of the downstream-signaling mo lecules AKT and MAP kinase in a CSF-1R 
transfected cell line. In vitro studies further demonstrated that LY3022855 inhibited monocyte 
proliferation and monocytic-t o-macrophage differentiation. 
 LY3022855 does not cross-react with murine CSF-1R, and thus  cannot be used in efficacy 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
18 studies in mice to explore the effects of targeting TAMs as a mechanism of inhibiting tumor 
growth. Therefore the surroga te rat monoclonal antibody CS7, which antagonizes murine CSF-
1R, was identified. CS7 binds murine CSF-1R with high affinity (K d = 0.8nM) and neutralizes 
CSF-1 binding activity in a solid-phase ligand- blocking assay. Cell-base d assays utilizing 
RAW264.7 cells, a murine macrophage-like cell line, showed CS7 blocked activation of CSF-1R 
in a dose-dependent manner with similar efficacy to LY3022855. In addition, in the presence of 
CS7, monocytes failed to differentiate into  macrophages and had reduced proliferative 
properties. Thus, CS7, by neutralizing activation of CSF-1R, can inhibit the proliferation and 
differentiation of murine monocytes into ma crophages in a manner similar to LY3022855 acting 
on human monocytes/macrophages and is an  appropriate surrogate antibody for in vivo  studies. 
 Non-clinical PD studies with CS 7 demonstrated the potential fo r CSF-1R targeted therapy in 
oncologic indications by reducing the number of TAMs in the tumor stroma and inhibiting the 
growth of tumor cells. Animal tumor model st udies focused initially on breast cancer models 
because scientific literature in dicates that breast cancers have high macrophage infiltration of the 
tumor stroma
28. Also, CSF-1 is often highly secreted in breast cancer, and elevated circulating 
CSF-1 is an indicator of poor  prognosis and high tumor grade28. Therefore, the hypothesis that 
the growth of tumors established with cell lines that secrete significan t amounts of CSF-1 would 
be inhibited by an antibody targ eting mouse CSF-1R (CS7) to a greater extent than tumors 
established with cell lines that express very lit tle or no detectable CSF-1 was investigated. Two 
human breast cancer ce ll lines, MDA-MB-231LP-OSPT a nd HCC1954, were chosen for 
xenograft animal models because of their high CSF-1 secretion levels. In both tumor models, 
CS7 showed a statistically significant dose-dependent suppression of tumor growth over those animals treated with the rat IgG control antibody. 
 Staining of the tumor and surrounding stroma with a macrophage-speci fic antibody revealed a 
dramatic decrease in macrophage infiltrati on in both MDA-MB-231LP-OS-PT and HCC1954 
tumor stroma. Thus, treatment of tumor-bearin g animals with CS7 leads to a decrease in 
macrophage infiltration, as antici pated. Similarly, non-tumor bearing Balb/c mice treated with 
CS7 demonstrated a decrease in Kupffer cells (t issue-resident macrophages in liver) within two 
weeks of thrice-weekly administration.  To estimate target serum concentrations for e fficacy in initial clinical investigations, trough 
concentrations associated with efficacy were determined in human breast cancer (HCC1954) and 
human leukemia (NKM-1) models established in mice. LY3022855 was evaluated in the leukemia model established following IV injec tion of CSF-1R expressing NKM-1 cells. The rat 
surrogate, CS7, was used in the breast cancer model established following subcutaneous injection of CSF-1R negative HCC1954 cells. The results from the two studies identified markedly different efficacious concentrations for the antibodies in the different models. The human NKM-1 model appeared very sensitive to the anti-tumor effect of LY3022855, as efficacy 
was achieved at mean trough concentrations down to 0.2 µg/mL. For CS7, notably higher doses and concentrations were required to inhibit human HCC1954 breast cancer tumor growth, as a 
mean trough concentration of 425 µg/mL was asso ciated with efficacy. Because the initial 
clinical investigation was in solid tumors, the hi gher concentration is regarded as a conservative 
target concentration for efficacy.  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
19  
2.2.2 Clinical Studies 
 
As of 28 January 2016, data are available from 43  patients who have received treatment in two 
Lilly-sponsored phase I studies of LY3022855 (St udy I5F-IE-JSCA hereby referred to as JSCA 
and Study I5F-MC-JSCB hereby referred to as JS CB), as summarized in Table 5. A third Lilly-
sponsored phase Ia/Ib study of LY3022855 (JSCC) will be initiated in 2016; no patients have 
been treated as of 28 January 2016. Please refer to  the most recent investigator’s brochure (IB) 
for further information.  
Table 5: Lilly-Sponsored Clinical Studies 
Study Number and 
Title Study Design Treatment Regimen Number of 
Patients 
Treated and 
Study Status
15F-IE-JSCA (JSCA) 
Phase I Study of 
LY3022855, a Monoclonal 
Antibody Targeted to the CSF-1 Receptor (CSF-
1R), in Patients With 
Advanced Solid Tumors Refractory to Standard 
Therapy or for Which No 
Standard Therapy Is Available Phase I, single-agent 
(monotherapy), 
dose-escalation study LY3022855 administered by IV infusion at the following dosages: 
 
Part A (weight-based dosing): Cohort 1  - 2.5 mg/kg weekly 
Cohort 2  - 0.3 mg/kg weekly 
Cohort 3  - 0.6 mg/kg weekly 
Cohort 4  - 1.25 mg/kg every 2 weeks 
Cohort 5  – 1.25 mg/kg weekly 
 Part B (non-weight based dosing): 
Cohort 6a  – 100 mg weekly (completed) 
Cohort 7a  – 150 mg weekly (ongoing) Study is 
ongoing. 
I5F-MC-JSCB (JCSB) 
Phase I Study to Identify 
the Immunomodulatory Activity of LY3022855 
(IMC-CS4) in Patients 
with Advanced, Refractory Breast or Prostate Cancer Phase I, single-
center, open-label, 
nonrandomized, noncontrolled study LY3022855 administered by IV infusion at 
the following dosages: 
Dosage A  - 1.25 mg/kg every 2 weeks 
Dosage B  - 1 mg/kg on weeks 1, 2, 4, and 
5 of every 6 week cycle Study is 
ongoing. 
15F-MC-JSCC  
A Phase Ia/Ib Trial 
Investigating the CSF-1R 
Inhibitor LY3022855 in Combination with 
Durvalumab (MEDI4736) 
or Tremelimumab in Patients with Advanced 
Solid Tumors Phase 1a/1b, multicenter, 
nonrandomized, 
open-label, dose-
escalation study followed by dose 
expansion (5 disease 
specific expansion cohorts) of IV 
LY3022855 in 
combination with IV In Part A (Dose Escalation, Phase 1a) of 
the study, LY3022855 QW, in 
combination with Durvalumab Q2W or 
Tremelimumab Q4W (after 6 doses, 
tremelimumab Q12W until discontinuation), is planned. 
Part B (Disease-Specific Expansion, Phase 
1b) of the study will include 5 expansion cohorts. Patients will be treated at the 
MTD identified for each combination in Study is ongoing. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
20 durvalumab or IV 
tremelimumab in patients with 
advanced cancer. Part A, unless otherwise specified by the 
sponsor. 
 
 2.2.2.1 
Pharmacokinetics 
 As of 28 January 2016, LY3022855 serum concentrations for non-compartmental analysis were available from 27 patients enrolled in Study JS CA within 5 Cohorts: 0.3  mg/kg QW (n=4), 0.6 
mg/kg QW (n=3), 1.25 mg/kg QW (n=5), 1.25 mg/ kg Q2W (n=9), and 2.5 mg/kg QW (n=6), and 
from 14 patients enrolled in Study JSCB within  2 Cohorts: 1.25 mg/kg Q2W (n=9) and 1 mg/kg 
on Weeks 1, 2, 4, and 5 of every 6-week cycle (n =5). Note that for patients in Study JSCA 
Cohort 4 and Study JSCB, only nominal time data (i.e., the intended sample collection time, 
rather than the actual collect ion time) were available. 
 In addition to non-compartmental analysis, LY 3022855 PK data were an alyzed using a PK 
modeling approach. LY3022855 in cancer patients e xhibited moderate tota l body clearance (CL) 
(mean values on Day 1 ranged from 0.0378 to 0.0651 L/h), low volume of distribution at steady 
state (V
ss) (mean values on Day 1 ranged from  2.85 to 4.93 L) and moderate t 1/2 (mean values on 
Day 1 ranged from 30.8 to 92.2 hours).  While the values for CL and t
1/2 appeared to be slightly larger  and smaller, respectively, than 
those typically observed for an IgG1 monocl onal antibody, the estimates of both CL and t 1/2 were 
likely confounded by the limited sampling period (between 168 hours and 336 hours, dependent 
on dosing frequency), and the high incidence of samples reported as below the quantifiable lower limit of the assay (BLQ) at lower doses.  By comparison of the non-compartmental PK parameters across each dose cohort, the CL 
ofLY3022855 appeared to be non-linear with respect to LY3022855 concentration, with 
higherdoses of LY3022855 exhibi ting lower CL values. Non-lin earity of LY3022855 CL with 
respect to concentration was al so observed in the model struct ure used for the PK/PD modeling 
analysis. However, this appa rent non-linearity was confounde d by the high incidence of 
concentrations reported as BLQ which could artifi cially inflate the calculated CL at lower doses. 
 The intra-patient accumulation ratio (R
A) for the 2.5-mg/kg QW regimen (1.97) was 
approximately twice that observed for the 1.25-mg/kg Q2W regimen (0.998). While this was 
approximately equal to the difference in the theoretical calculated accumulation index for a 
molecule with a 7-day t 1/2 which was dosed QW versus Q2W, the 2 cohorts also received 
different dose levels, and thus the potential eff ect of dose non-linearity in CL on this difference 
in R A could not be disregarded. 
 An apparent lack of relationship between pa tient body weight and LY3022855 CL resulted in an 
amended dose escalation plan for Study JSCA to  evaluate the safety, PK , and immunogenicity of 
LY3022855 using a flat dosing approach (i.e., mg as opposed to mg/kg). Please see IB for further information.  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
21 2.2.2.2 Pharmacodynamics 
 
All patients receiving LY3022855 in Study JSCA exhibited elevated serum CSF-1 and IL-34 
levels, suggesting CSF-1R target engagement across a 0.3 to 2.5-mg /kg dose range. The extent of 
serum CSF-1 and IL-34 elevation increased with  increasing dose. The duration of serum CSF-1 
and IL-34 elevation was dependent on dosing frequency, where dosing every week yielded 
increased and sustained serum CSF-1 and IL-34 el evations over dosing every 2 weeks. At higher 
serum concentrations of LY3022855 (i .e., higher doses and earlier time points), inter-individual 
variability in patient CSF-1 PD response was reduced.  In addition, inhibition of non-classical CD14
dimCD16bright monocytes occurred with increasing 
dose and was sustained with increased dosi ng frequency, where dosing every week yielded 
increased and sustained suppression of CD14dimCD16bright monocytes over dosing every 2 weeks. 
This indicated that sustained target engagement yielded sustained biological response, as 
measured by inhibition of CD14dimCD16bright monocytes. 
 2.2.2.3 
Pharmacokinetic/Pharmacodynamic Model  
Patients receiving LY3022855 acros s the dose range tested (0 .3 to 2.5 mg/kg) exhibited 
increased levels of serum CSF-1 after single and multiple doses of LY3022855, with the extent 
of CSF-1 elevation increasing w ith increasing dose level and dos ing frequency. Since CSF-1 is a 
ligand of CSF-1R, it is thought that  the increase in serum concentra tions of this marker showed 
evidence of CSF-1R target engagement. A PK/PD model was therefore developed to quantify the 
relationship between LY3022855 dose, LY3022855 se rum concentrations, and serum CSF-1 
levels.  The PK/PD dataset comprised PK and CSF-1 data  which were available as of 28 January 2015. 
This dataset included 24 patients enrolled on St udy JSCA: 2.5 mg/kg QW (n=6), 0.3 mg/kg QW 
(n=4), 0.6 mg/kg QW (n=3), 1.25 mg/kg Q2W (n=6) and 1.25 mg/kg QW (n=5). Rich sampling was performed for both PK and CSF-1 across single and multiple doses of LY3022855.  The PK of LY3022855 was characterized by a two-compartment model with non-linear 
clearance. The Michaelis-Menten constant (K
M) for non-linear LY3022855 clearance was 
approximately equal to 30 µg/mL, correspond ing to doses above 1.25 mg/kg. However, this 
apparent non-linearity in CL ma y have been confounded by the high incidence of concentrations 
reported as BLQ which could have  artificially inflated the ca lculated CL at lower doses. 
 LY3022855-mediated elevations of CSF-1 were best  described by an indirect response model, 
where the action of LY3022855 was incorporated as inhibition of CSF-1 elimination. The model 
indicated potent and comple te inhibition of CSF-1 elimination by LY3022855, and a steep 
concentration-response curve. The model-estimated LY3022855 concentration at which 50% inhibition of CSF-1 elimination occurs (IC
50) (approximately equal to 1.4 µg/mL) was lower 
than the PK assay limit of quantification, and thus the lowest dose that could sustain this 
LY3022855 concentration across the dosi ng period is not known, but is predicted to be as low as 
0.3 mg/kg QW. However, model si mulations showed that, of the doses tested, the 1.25-mg/kg 
QW dose was the lowest dose associated with  sustained CSF-1 elev ation across the dosing 
interval in the majority of patients. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
22  
Although the PK/PD model suggests complete inhibition of CSF-1 elimination by LY3022855, the extent of serum CSF-1 elevation continue d to increase with increasing dose. The model 
suggests that this phenomenon is due to cont inued production of serum CSF-1, rather than 
insufficient inhibition of the target, CSF-1R.  2.2.2.4 
Safety 
 Study JSCA 
 As of 09 September 2016  total of 369 patient s have received LY3022855 in the phase I dose 
escalation study of LY3022855 in advanced solid tu mors (study JSCA). This study is currently 
ongoing.  In cohort 1, two of the first three patients experienced Common Terminology Criteria for 
Adverse Events (CTCAE) grade 2 elevations of serum CPK, AST (Grade 1 - 2) and LDH. Due 
to these serum enzyme elevations and the genera l conditions of the patie nts involved, two of the 
first three patients enrolled did not complete cycle 1. 
 Per protocol, three additional patients were treat ed in cohort 1. These additional patients also 
exhibited elevated levels of CPK, AST, and LDH. In one patient, serum levels of CPK and AST reached grade 3; however, this was not cla ssified as a dose-limiting toxicity (DLT) upon 
comprehensive clinical evaluation of the patient du e to the lack of clinical signs and symptoms 
of organ toxicity. Furthermore, enzyme le vels decreased upon discontinuation of LY3022855, 
indicating that these effects were reversible.  Since pre-clinical studies with LY3022855 in monk eys demonstrated a dose-response correlation 
between the dose of LY3022855 and the increase in serum enzyme levels, continued dose 
escalation in the JSCA trial was considered likely to result in a DLT. Therefore, it was 
considered medically prudent not to dose escala te beyond cohort 1 with th e originally planned 
dosage schedule, which was 5, 10, 20, and 30 mg/kg on ce weekly. In order to better characterize 
the LY3022855 dose-response effect on the mono cyte/macrophage system and on various 
serologic and hematologic parameters, the dosing scheme and schedule for study JSCA were revised to reflect dose reductions an d prolonged administration intervals. 
 Under the revised dose-escalation plan, the dosages  for subsequent dose explorations were as 
follows: cohort 2 (0.3 mg/kg QW), cohort 3 (0.6 mg/kg QW), Cohort 4 (1.25 mg/kg Q2W), Cohort 5 (1.25 mg/kgQW), and Cohort 6 (2.5 mg/kg Q2W). The addition of every-2-week 
dosing was considered appropriate based on the relatively long t
1/2 observed in cynomolgus 
monkeys.  In cohort 4, a DLT for LY3022855 was declared in  one patient with a history of cardiac 
dysfunction who developed a grade 3 left ventri cular systolic dysfuncti on after one dose of 
LY3022855. Two DLT events were observed in cohort 5: one patient  developed grade 4 
rhabdomyolysis and acute renal failure and one patient developed grad e 3 pancreatitis. The 
original recommended phase II dose for LY3022855 was determin ed to be 1.25 mg/kg every 2 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
23 weeks. However, subsequent analysis of clinical data suggested sub-maximal target engagement 
on a Q2W schedule as opposed to QW dosing. Add itionally, exploratory graphical analysis of 
the PK of LY3022855 in weight-based dosing Cohor ts 1 to 5 indicated no clear relationship 
between body weight and drug clearance. Therefore,  additional cohorts were added (Part B of the 
study) in a protocol amendment, Version 7.0, to  evaluate safety, PK, and PD of non-weight 
based dosing of LY3022855 administered on a weekly schedule.  Study JSCB 
 Study JSCB is a Phase 1 study to identify th e immunomodulatory activity of LY3022855 in 
patients with advanced, refractor y breast or prostate cancer. As of the data cut-off date, 28 
January 2016, 9 patients have been treated with 1.25 mg/kg LY3022855 Q2 W of every 6-week 
cycle and 5 patients have been treated w ith 1 mg/kg LY3022855 on Weeks 1, 2, 4, and 5 of 
every 6-week cycle. Patients treated with  1.25 mg/kg LY3022855 Q2W were observed to have 
elevated CK, AST, and LDH levels. In 1 patien t, serum levels of CK reached Grade 3 on 2 
occasions. For each of these occasions, study drug was subsequently held and the event resolved. 
Please refer to the IB for more informa tion.  Enrollment to this study is ongoing. 
 
Deaths  
 
As of the data cut-off date of 28 January 2016, three deaths occurred on the JSCA study or 
within 30 days after the last dose of LY3022855. One death each, due to progressive disease, 
occurred in patients enrolled in  the 0.3 mg/kg weekly dose cohor t (cohort 2), 0.6 mg/kg weekly 
dose cohort (cohort 3), and 1.25 mg/kg weekly dose cohort (cohort 5). In addition, two deaths were reported post completion of the study. The patients died after more than 30 days of 
receiving the last dose of LY3022855 due to prog ressive disease. One of the patients was 
enrolled in the 0.3 mg/kg weekly dose cohort (c ohort 2), and the other in the 1.25 mg/kg every 2 
weeks dose cohort (cohort 4).No de aths occurred while patients were on study treatment in trial 
JSCB or within 30 days after the last dos e of LY3022855, and no deaths were reported post 
completion of study participation.  
Serious Adverse Events 
 
As of the data cut-off date of 28 January 2016, Ni ne patients who received at least one dose of 
LY3022855 in study JSCA experienced a total of 15 treatment-emergent serious adverse events 
(SAEs): grade 2 toxicity to various agents a nd tremor, and grade 3 as cites (cohort 2, 0.3 mg/kg 
QW); grade 3 tachycardia, pneumothorax, and hypotension and grade 5 sudden death (cohort 3, 
0.6 mg/kg QW); grade 3 left ventricular dysfunc tion, confusional state, and small intestinal 
obstruction (cohort 4 and the MTD expansion cohor t, 1.25 mg/kg Q2W); and grade 2 fatigue and 
mental status changes, grade 3 pancreatitis, a nd grade 4 rhabdomyolysis and acute renal failure 
(cohort 5, 1.25 mg/kg QW).   Of these 15 SAEs, 8 SAEs reported in 5 patients were considered at least possibly related to 
LY3022855: tachycardia, hypotension, and sudden deat h (1 patient, Cohort 3); left ventricular 
dysfunction (1 patient, Cohort 3); rhabdomyolysis  and acute renal failure (1 patient, Cohort 5); 
pancreatitis (1 patient, Cohort 5); and confusional state (1 pa tient, MTD expansion cohort). The 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
24 sudden death occurred after the patient had co mpleted the DLT assessment period (i.e., had 
received all scheduled treatment s for cycle 1 and completed the observation period, as needed). 
The treating investigator felt that the death was most likely related to disease progression of the 
underlying sarcoma.  
 In study JSCB, two patients with breast cancer who received at least 1 dose of LY3022855 (1.25 
mg/kg Q2W) experienced 8 treatment-emergent  SAEs: anemia, cardiomyopathy, confusional 
state, encephalopathy, femur fracture, hemorrhage, pain, and pain in the extremity (all Grade 3). 
Of the 8 SAEs, 2 SAEs (cardiomyopathy and en cephalopathy) reported in 1 patient were 
considered by the investigator to be  at least possibly related to LY3022855. 
 
Treatment-Emergent Adverse Events 
 
As of 28 January 2016, 28 of the 29 patients (96.6%) treated with LY3022855 in study JSCA 
experienced at least one treatment-emergent adve rse event (TEAE). Please refer to the IB for a 
comprehensive list of advers e events. Of the 29 patients treated with LY3022855, 22 patients 
(75.9%) experienced at least one AE considered at least possibl y related to treatment with 
LY3022855. This data is summarized below. Th e most commonly reported possibly study drug-
related TEAEs ( ≥ 20% of patients) regardless of grad e were fatigue, AST increased, and blood 
CPK increased, and nausea. Among all grade 3 and grade ≥ 4 AEs, the following AEs reported in 
a total of 7 patients (24.1%) were considered related to LY3022855: grade 3 AST increased and 
blood CPK increased (cohort 1); grade 3 hypotensi on, subcutaneous abscess, and tachycardia 
(cohort 3); grade 5 sudden death (cohort 3); grad e 3 confusional state and left ventricular 
dysfunction (cohort 4 and the MTD expans ion cohort); grade 3 hypophosphatemia and 
pancreatitis (cohort 5); and gr ade 4 acute renal failure a nd rhabdomyolysis (cohort 5). 
 
In study JSCB, all 14 participants treated with  LY3022855 experienced at least 1 TEAE. Twelve 
of 14 patients experienced at leas t 1 AE considered at least possi bly related to treatment with 
LY3022855. The most common TEAEs considered to  be at least possibly study drug-related 
(≥20% of patients), regardless of  grade, were: fatigue, nausea,  blood CPK increased, decreased 
appetite, diarrhea, lipase increa sed, and periorbital edema. The following Grade 3 AEs reported 
in 5 of 14 patients were considered at leas t possibly related to LY3022855: amylase increased, 
blood alkaline phosphatase increased, blood CPK increased, cardiomyopathy, and 
encephalopathy, and fatigue.  Of the 29 patients treated with LY3022855, 4 pati ents (13.8%) were di scontinued from study 
drug due to AEs. One patient treated with LY3022855 at the weekly dose of 2.5 mg/kg (cohort 
1) was discontinued from study dr ug due to the AEs of elevated CPK, AST, and LDH; all AEs 
were considered probably related to the st udy drug. One patient was discontinued from study 
drug due to cognitive disorder (c onsidered unrelated to the study drug). Two patients treated with 
LY3022855 at the weekly dose of 1.25 mg/kg (cohort 5) discontinued study therapy due to acute 
renal failure (as a consequence of rhabdomyolysis) and pancreat itis that were probably and 
possibly related to study drug, respectively.  In study JSCB, no patient was disc ontinued from LY3022855 due to AEs. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  25 
 Table 6: Related TEAEs by Cohort for Study JSCA Occurring in ≥ 2 Patients (N = 29) 
 
 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
26  
Table 7: Related TEAEs by Cohort for Study JSCB Occurring in ≥ 2 Patients (Safety Population, N = 14) 

DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  27 
 2.2.2.5 Efficacy 
 
No efficacy information is available as of 28 January 2016. 
 2.2.2.6 
Drug Interactions 
 No formal drug interaction studies have been performed with LY3022855 in humans.  
 2.3 
Vemurafenib 
 
Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of 
BRAF  serine threonine kinase, including BRAF V600E. Vemurafenib also inhibits other kinases 
in vitro  such as CRAF, ARAF , wild-type BRAF, SRMS, ACK1, MAP4K5 , and FGR at similar 
concentrations. Some mutations in the BRAF  gene including V600E result in constitutively 
activated BRAF proteins, which can cause cell prolif eration in the absence of  growth factors that 
would normally be required for pr oliferation. Vemurafenib has anti -tumor effects in cellular and 
animal models of melanomas with mutated BRAF V600E. 
 Vemurafenib has been FDA approved for patient s with unresectable or metastatic melanoma 
with a BRAF V600E  mutation and is commercially available. Please reference the FDA package 
insert for background information. Agent will be administered per standard of care guidelines in accordance with institutional standards and the FDA prescribing information. 
  
2.4 
Cobimetinib 
 
Cobimetinib (Cotellic) is a reversible inhibito r of MAPK/ MEK1 and MEK2. MEK proteins are 
upstream regulators of the extracellular signal re lated kinase (ERK) pathway, which promotes 
cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the 
BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines 
expressing BRAF V600E, cobimetinib inhi bited tumor cell growth. 
 
Cobimetinib and vemurafenib target two differe nt kinases in the RA S/RAF/MEK/ERK pathway. 
Compared to either drug alone, co-administratio n of cobimetinib and vemurafenib resulted in 
increased apoptosis in vitro and reduced tumor growth in mouse implantation models of tumor 
cell lines harboring BRAF V600E mutations. Cobimetinib also prevented vemurafenib-mediated 
growth enhancement of a wild-type BRAF  tumor cell line in an in vivo  mouse implantation 
model.  Cobimetinib has been FDA approved for patients w ith unresectable or metastatic melanoma with 
a BRAF V600E or V600K mutation and is commercially available. Please reference the FDA 
package insert for background information. Agent will be administered per standard of care guidelines in accordance with institutional st andards and the FDA prescribing information. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
28 2.5 Rationale 
 
The tumor microenvironment is know n to play a role in innate or acquired resistance to BRAF 
inhibition29,30. Tumor cells can control the surrounding milieu by producing cytokines that 
suppress cytolytic T-cells and recruit immunosuppre ssive cells, and CSF-1 is one such cytokine 
that is secreted by melanoma. CSF-1 induces  the proliferation and differentiation of 
immunosuppressive myeloid cells, such as M2  polarized macrophages and myeloid-derived 
suppressor cells (MDSCs), by binding to CSF-1R on the surface of the cell. This results in the 
ability of the tumor cell to evade the immune response and allows for subsequent metastasis31.  
 Pre-clinical data by Mok et al. showed a drama tic reduction in tumor infiltrating myeloid cells 
when treated with CSF-1R inhibi tion.  When this was combined with BRAF inhibition superior 
antitumor responses and increased tumor-infiltrating lymphocytes were observed
31. Inhibitors to 
CSF-1R have been shown to deplete certain popu lations of TAMs and in established tumors, the 
combination of CSF-1R inhibitors with chemot herapy has been shown to dramatically enhance 
responses32.  
 Additional pre-clinical data from Wang et al. demonstrated th at macrophages play a role in 
resistance to BRAF inhibitor therapy through paradoxical activ ation of the MAPK pathway 
leading to increased production of vascular endothelial growth  factor (VEGF).  Targeting 
macrophages in a pre-clinical mode l led to increased tumor activity of BRAF inhibition in mouse 
and human tumor models
33. These data together suggest that targeting macrophages in 
combination with BRAF inhibition in patients wi th melanoma may reduce baseline resistance 
and increase efficacy. Prior BRAF inhibition has also been shown to lead to increased TAMs, 
suggesting a potential role of  combination therapy in pati ents with acquired resistance34. 
 
2.5.1 LY3022855 Flat Dosing Rationale 
 LY3022855 was initially dosed per body weight . However, Study JSCA (Version 7.0) was 
amended to explore a non-weight based dosing scheme based upon clinical data.  
 As of 14 August 2016, LY3022855 serum concentrations for non-compartmental analysis were available from 33 patients enrolled in Study JS CA within 7 cohorts:  0.3 mg/kg QW (N=4), 0.6 
mg/kg QW (N=3), 1.25 mg/kg QW (N=5), 1.25 mg/kg every 2 weeks (Q2W) (N=11), 2.5 mg/kg QW (N=6), 100 mg QW (N=3), and 150 mg QW (N=1).  The non-compartmental PK parameters 
stratified by dosing regimen and day of PK sample collection for Study JSCA are provided in 
Table 8 .  Mean LY3022855 serum concentration-time profiles on Day 1 and on Day 15 or 22 for 
Study JSCA are presented in Figure 1. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  29 
  Table 8: Summary of Non-compartmental PK Parameters Following IV Infusion of Weight-Based and Non-
Weight-Based of Dosing LY3022855 in Cancer Patients during Cycle 1 for Study JSCA 
 Geometric Mean 
(CV%)
Treatment 0.3 mg/kg 
QW 0.6 mg/kg 
QW 1.25 mg/kg 
QW 1.25 mg/kg 
Q2W 2.5 mg/kg 
QW 100 mg 
QW 150 mg 
QW 
Cohort 2 3 5 4 1 6a 7a 
Day 1 1 1 1 15 1 22 1 84 or 99 1 
N 4 3 5 11 10 6 4 3 2 1 
Parameter           
C168h, µg/mL NC NC  
(5.68 and 3.41)a 3.32 
(11)b 3.35 
(22)c 14.4 
(34) 50 
(25)d  
(1.77 and 6.11)a 7.71e NC 
Cmax, µg/mL 6.83 
(32) 13.5 
(33) 26.0 
(14) 30.7 
(24) 30 
(25) 69.2 
(13) 92.7 
(23) 34.6 
(25)  
(42.8 and 31.2) 42.7 
tmaxf, h 0.01 
(0.01-
1.02) 2.02 
(0.01-
2.08) 1.01 
(0.01-21.6) 0.01 
(0.01-2) 1.00 
(0.01-2) 0.75 
(0.01-8.00) 0.97 
(0.50-2.00) 0.960 
(0.01-2)  
(0.01 and 1.07) 2.02 
t1/2g, h 30.9d 
(25.2-44) 30.8 
(23.6-
36.2) 58.3 
(45.5-85.3) 41.4 
(21.5-67.3) 46.9h 
(24.3-109) 85.0 
(56.6-126) 196 
(132-346) 48.2 
(35.9-69.9) 82.8e 38.7 
Cav,τ, µg/mL 1.53d 
(15) 2.91 
(24) 10.8 
(21) 4.72 
(50) 5.06h 
(49) 29.9 
(18) 55.8 
(41) 10.5 
(28) 18.9e 13.2 
AUC (0-∞), 
h·µg/mL 264d 
(17) 500 
(24) 2130 
(28) 1600 
(50) 1730h 
(52) 6860 
(26) 21200 
(73) 1970 
(37) 4150e 2330 
AUC (0-τ)i, 
h·µg/mL 257d 
(15) 489 
(24) 1810 
(21) 1590 
(50) 1700h 
(49) 5030 
(18) 9370 
(41) 1770 
(28) 3170e 2220 
CL, L/h 0.107d 
(21)  0.0720 
(30) 0.0561 
(31) 0.0559 
(33) 0.0516h 
(36) 0.0378 
(25) 0.0203 
(34) 0.0566 
(28) 0.0315e 0.0676 
Vss, L 4.71d 
(9) 3.15 
(10) 4.72 
(12) 3.39 
(22) 3.37h 
(20) 4.67 
(37) 5.70 
(19) 3.88 
(23) 3.68e 3.77 
RA NC NC NC NC 1.04h, j 
(18) NC 1.82c, k 
(27) NC 2.29e, l NC 
Abbreviations:  AUC (0- τ) = area under the concentration versus  time curve from time zero to τ; AUC (0- ∞) = area under the concentration versus time curve from time zero to ∞; C 168h = serum 
concentration collected 168 hours following the start of infusion; C av,τ = average serum concentration over dosing interval calculated using AUC (0-τ); CL = total body clearance; C max = maximum 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
30  Table 8: Summary of Non-compartmental PK Parameters Following IV Infusion of Weight-Based and Non-
Weight-Based of Dosing LY3022855 in Cancer Patients during Cycle 1 for Study JSCA 
 Geometric Mean 
(CV%)
Treatment 0.3 mg/kg 
QW 0.6 mg/kg 
QW 1.25 mg/kg 
QW 1.25 mg/kg 
Q2W 2.5 mg/kg 
QW 100 mg 
QW 150 mg 
QW 
Cohort 2 3 5 4 1 6a 7a 
Day 1 1 1 1 15 1 22 1 84 or 99 1 
N 4 3 5 11 10 6 4 3 2 1 
serum concentration; CV = coefficient of variation; h = hours; N = number of patients; NC = not calculable; Q2W = once every 2 weeks; QW = once weekly; R A = intrapatient accumulation 
ratio; t 1/2 = terminal elimination half-life; t max = time of maximum serum concentration; V ss = volume of distribution at steady-state. 
a N=2; reported as individual parameter estimates. 
b N=5. 
c N=4. 
d N=3. 
e N=1; reported as individual parameter estimate. 
f Median (Minimum – Maximum). 
g Geometric Mean (Minimum – Maximum). 
h N=9. 
i τ = 168 h for QW regimen; τ  = 336 h for Q2W regimen. 
j RA = AUC (0-τ),day 15/ AUC (0-τ),day 1. 
k RA = AUC (0-τ),day 22/ AUC (0-τ),day 1. 
l RA = AUC (0-τ),day 84 or day 99 / AUC (0-τ),day 1. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  31 
  
LY3022855 in cancer patients exhibits pharmacokinetic properties cons istent with those 
typically expected for an IgG1 antibody, with mean total body clearance (CL) after a single dose ranging from 0.0378 to 0.107 L/h, mean volume of distribution at steady state (V
ss) after a single 
dose ranging from 3.15 to 4.72 L, and mean half life (t 1/2) after a single dose ranging from 30.8 
to 85.0 hours.  LY3022855 CL appears to be non-linea r with respect to dose, with higher doses 
of LY3022855 exhibiting lower CL values ( Figure 2 ).  These results are in accordance with the 
previous PK analysis for Cohorts 1 to 5, as  detailed in the Inve stigator’s Brochure. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
32  
Abbreviations:  h = hours; N = number of patient s treated; QW = once week ly; Q2W = once every 2 
weeks. 
Figure 1: Mean concentration-versus-time profiles for LY3022855 
following intravenous administration to patients with cancer on Day 1 
(upper panel) and on Days 15 and 22 (lower panel) for Study JSCA . 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
33 These updated results indicate an apparent lack of relationship between patient body weight and 
LY3022855 CL ( Figure 2 ), consistent with previous anal yses.  Moreover, the PK of LY3022855 
in patients receiving a non-weight-based dose of 100 mg QW (Cohort 6a) and the weight-based 
dose of 1.25 mg/kg QW (Cohort 5) appears comparable (Figure 1).  The AUC (0-τ), Cmax, tmax, and 
t1/2 values are consistent between the 2 cohorts, further demonstra ting a lack of a relationship 
between patient body weight and serum LY3022855 concentration exposure. Taken together, 
these analyses provide suppor t for the exploration of LY 3022855 using a non-weight-based 
dosing approach.  Similar findings with monoclonal antibodies have been reported by others
35-38. Wang and 
colleagues investigated 12 monoclonal antibodi es and found that fixed and body size-based 
Abbreviations:  N = number of patients treated; QW = once weekly; Q2W = once every 2 weeks. 
Figure 2: Individual observed clearance versus patient body weight 
(upper panel) and LY3022855 dose (lower panel) for Study JSCA. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
34 dosing perform similarly, with fixed dosing being better fo r 7 of 12 antibodies36. In addition, 
they investigated 18 therapeutic proteins and pe ptides and showed that  fixed dosing performed 
better for 12 of 18 in terms of reducing the be tween-subject variability in PK/pharmacodynamic 
parameters37. 
 
A fixed dosing approach is preferred by the pr escribing community due to ease of use and 
reduced dosing errors. Given expectation of sim ilar PK exposure and variability, we considered 
it feasible to switch to fixed dosing regimens.  
2.5.2 
LY3022855 Flat Dosing Safety 
 Updated safety analyses for patients treated in the flat dosing cohorts for Study JSCA (data cut 
off date of  06 September 2016)  are available; including 3 patient s treated in Cohort 6a (100 mg 
weekly [QW]) and 3 patients treate d in Cohort 7a (150 mg QW).   
 
LY3022855 administered at a flat dose on a weekly  schedule has not re sulted in any adverse 
events that led to permanent discontinuation of study treatment.  Only one patient who received 
flat weekly dosing of LY3022855 experienced an  AE (elevated lipase) resulting in a dose 
reduction.  The most common treatme nt emergent adverse events (all grades, with a minimum 
incidence of 33%) for patients treated with flat weekly dosing were: anemia (4 – 67%), nausea (3 
– 50%), fatigue (3 – 50%), constipation (2 – 33 %), lipase elevation (2 – 33%), hypoalbuminemia 
(2 – 33%), hypocalcemia (2 – 33%), and back pa in (2 – 33%).  The majority of these TEAEs 
were Grade 1 or 2. The incidence of Grade 3 ev ents were: anemia (2 – 33%), nausea (0%), 
fatigue (2 – 33%), constipation (0%), lipase eleva tion (1 – 17%), hypoalbuminemia (0%), 
hypocalcemia (0%), and back pain (0%).  A summ ary of all-cause seriou s treatment-emergent 
adverse events for flat doses are presented in th e table below.  Two patients treated at a dose of 
100mg QW experienced 4 serious treatment-emergent  AEs.  One patient  experienced an SAE of 
pulmonary hemorrhage (Medical Dictionary for Regulatory Activities Preferred Term [MedDRA 
PT]), and the second patient, experienced SAEs  of abdominal discomfort, C-reactive protein 
increased, and upper gastrointestinal (GI) hemorrhage (all are MedDRA PTs). 
 No DLT events were reported for patients trea ted at a dosage of 100mg QW.  One out of three 
patients treated at a dosage of 150mg QW expe rienced a DLT event of Grade 3 serum creatine 
kinase (CK) elevation associated  with elevated urine and serum myoglobin.  As a result of this 
one DLT, 3 additional patients are planned to  be enrolled to the 150mg QW dose level. 
 Dose levels for LY3022855 in this  protocol are detailed in 5.1 and are not planned to exceed the 
100 mg weekly dose that has thus far been show n to be tolerable in study JSCA. As a result 50 
mg QW is an appropriate initia l dose for LY3022855 for this study. 
  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  35 
 Table 9: Study JSCA:  Summary of Serious Trea tment-Emergent Adverse Events for Flat Doses 
Summary of Serious Treatment-Emergent Adverse Events for Flat Dose. - Study I5F-IE-JSCA/CP24-1001                      
Safety Population                                                                                                 13:51 07SEP20 16 
                                                                                                                             TD TM 
      _______________________________________________________________________________________________________________________                                                            100 mg weekly                          150 mg weekly                                                                (N=3)                                  (N=3)                                                                 n(%)                                   n(%)                                                ______________________________________ ______________________________________      SOC/Preferred Term                        All Grades   Grade =3     Grade >=4    All Grades   Grade =3     Grade >=4      _______________________________________________________________________________________________________________________       Patients with any AE                        1 ( 33.3)    0            0            1 ( 33.3)    1 ( 33.3)    0 
 
     Gastrointestinal disorders                  0            0            0            1 ( 33.3)    1 ( 33.3)    0         ABDOMINAL DISCOMFORT                     0            0            0            1 ( 33.3)    1 ( 33.3)    0         UPPER GASTROINTESTINAL HAEMORRHAGE       0            0            0            1 ( 33.3)    1 ( 33.3)    0       Investigations                              0            0            0            1 ( 33.3)    0            0         C-REACTIVE PROTEIN INCREASED             0            0            0            1 ( 33.3)    0            0       Respiratory, thoracic and mediastinal       1 ( 33.3)    0            0            0            0            0      disorders         PULMONARY HAEMORRHAGE                    1 ( 33.3)    0            0            0            0            0              
 
     _______________________________________________________________________________________________________________________ Note 1: For each SOC and Preferred Term, each patient was counted only once according to the worst grade of the TEAE. Note 2: All Grades column includes patients with missing CTC grades as well. Data cut-off date: September 6, 2016. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  36 
 2.6 Correlative Studies Background 
 
Use of immune and targeted ther apies in patients with genomically complicated tumors presents 
a variety of confounding variables that could cont ribute to success or failure of the therapy.  
Correlative studies are designed to both enable better understanding of the possible reasons that 
LY3022855 in combination with vemurafenib and c obimetinib may prove to be effective or 
ineffective in individual patients, and to enab le the development of mo re effective targeting 
strategies in the future.    
Collection of Tumor Tissue 
 
In order to retrospectively e xplore the determinants of re sponse and resistance to LY3022855 
combination therapy, archival tumor tissue will be collected at baseline from all patients 
enrolling to the trial. In add ition, optional fresh tumor biopsies will be obtained from patients 
enrolled to either the phase I or phase II portion of the trial. These biopsies will be obtained on-treatment and again at the time of disease prog ression. The genetic and immune characteristics 
identified in the tumor tissue will be  correlated to clinical outcome. 
 
Analysis of tumor tissue samples taken at distin ct points enables addressing of key questions 
including: (1) the genomic lesions and immune cell presence at baseline in samples studied and their potential impact upon res ponse, (2) the identif ication of immediate pathways/gene 
expression programs activated by tumors fo llowing LY3022855 combination therapy, and (3) 
mechanisms of acquired resistance to therapy.  The first correlative question relates to the genetic and immune diversity of the patients enrolled in this study. It is the anticipation that most  patients on this study will have had their tumor 
genomically characterized by either the OncoPane l test at DFCI/BWH (a custom hybrid capture 
panel which via next-generation sequencing will identify mutati ons and copy-number alterations 
in cancer associated genes) or via another CLIA-c ertified method at the time of enrollment. The 
archival tissue collected will be analyzed to l ook at the TAMs present at baseline. Macrophages 
are among the most abundant normal cells in the tumor microenvironment. Substantial evidence 
has indicated that macrophages adopt a pro-tu moral phenotype, suppressing T cell response and 
promoting tumor progression via angiogenesis, tumor cell invasion, motility, intravasation, and 
promotion of persistent growth
32. The levels of certain TAMs present at baseline can be 
correlated to the clinical  response observed with the combin ation therapy, and this data may 
enable us to identify immune characteristic s that may also impact  clinical response. 
 Another key rationale for performance of biopsies in patients after initia ting drug therapy is to 
address mechanisms of resistance to LY3022855 combination therapy.  The emergence of 
resistance to therapy is a profound problem in  oncology.  Such resistance can follow not only 
acquisition of secondary mutations but also from the ability of can cer cells to activate immediate 
compensatory signaling tracts following targeted inhibition of a key pathway
39. Identification of 
these compensatory reactions is a necessary step in order to de sign subsequent rational therapies 
that may lead to even more durable and long-lasting clinical benefit. The optional on-treatment 
tissue samples will be examined for changes in MA PK activation as well as levels of TAMs and 
tumor immune infiltrates. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
37  
Optional biopsies obtained at the time of diseas e progression will be used to characterize the 
change in the tumor at the time of resistance.  Such changes could stem from the acquisition of 
novel genomic alterations, from activation of ot her signaling pathways, or  the production of anti-
inflammatory and immunosuppressive mediators.  Biopsies obtained at progression will be 
analyzed for MAPK reactivation, other mechanisms of resistance (e.g., alternate kinase domain mutations), and tumor immune infiltrates. The information collected from these biopsies will be vital to understanding the methods of resistance to the comb ination therapy and planning 
subsequent treatment strate gies in this population. 
 
Collection of Blood 
 
Cell-free DNA (cfDNA) will be collected and analyzed for BRAF  V600E or V600K mutations. 
Levels of tumor DNA will d ecline longitudinally over time if th ere is a response to the treatment 
administered. To further assess this concept, pl asma will be collected from participants to 
evaluate whether circulating free plasma DNA declines with  the administration of LY3022855, 
vemurafenib, and cobimetinib and this information will be compared to clinical outcome.  Blood samples will also be collected to look at circulating immune cells including MDSCs. MDSCs are a heterogeneous group of myeloid-derived cells wh ich are greatly expanded in 
experimental models of cancer. Studies in humans carried out thus far have reported an increased 
frequency as well as immune-suppr essive activity in some of the myeloid-derived subsets of 
MDSCs present in the peripheral blood of patients with cancer.  In the case of metastatic 
melanoma, both monocytic as well as granul ocytic blood MDSCs with immune-suppressive 
function have been studied independently and proposed to exert an immune-regulatory role
40. To 
further explore the relationship of circulating immune cells including MD SCs and their potential 
correlation to clinical outcomes, peripheral blood levels will be serially collected from patients 
enrolled to the trial.   
3. 
PARTICIPANT SELECTION 
 
3.1 Eligibility Criteria  
 
Baseline evaluations are to be c onducted within 14 days prior to start of protocol therapy, with 
the exception of the informed consent, echoc ardiogram, ophthalmologic exam, and baseline 
tumor imaging which may be obtained up to 28 days  prior to the start of  protocol therapy. 
 
3.1.1 For enrollment to the phase I portion: participants must have a histologically confirmed melanoma with a BRAF  V600E or BRAF V600K mutation (identified via 
NextGen sequencing using the DFCI/BWH On coPanel or any CLIA-certified method) 
that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
38 3.1.2 For enrollment to the phas e II portion: participants must have a histologically 
confirmed melanoma with a BRAF  V600E or BRAF V600K mutation (identified via 
NextGen sequencing using the DFCI/BWH On coPanel or any CLIA-certified method) 
and cannot have received prior BRAF or MEK inhibitor therapy. 
 
3.1.3 Participants enrolling to the phase I por tion of the trial must have evaluable or 
measurable disease (see 11 for definitions). 
 
3.1.4 Participants enrolling to the phase II portion of  the trial must have measurable disease, 
defined as at least one lesion that can be accu rately measured in at least one dimension 
(longest diameter to be recorded for non-noda l lesions and short ax is for nodal lesions) 
as ≥ 10 mm with spiral CT scan, MRI, or calipers by clinical exam.  See 11 for the 
evaluation of measurable disease. 
 
3.1.5 Age ≥ 18 years. As no dosing or adverse event data are currently available in 
participants < 18 years of age, children are excluded from this study but will be 
eligible for future pediatric trials.   
 
3.1.6 ECOG performance status 0 - 1 (see APPENDIX A  PERFORMANCE STATUS 
CRITERIA ). 
 
3.1.7 Participants must have normal organ and marrow function as defined below: 
 
 Absolute neutrophil count  ≥ 1.5 K/uL 
 Platelets ≥ 100 K/uL 
 Hemoglobin ≥ 9 g/dL 
 Total bilirubin ≤ 1.5 × institutional uppe r limit of normal (ULN) 
 AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN 
 Serum creatinine ≤ 1.5 × institutional ULN 
 PT-INR ≤ 1.5 × institutional ULN (for participants on 
   anticoagulation therapy, ≤ 1.5 × their baseline value) 
 aPTT ≤ 1.5 × institutional ULN (for participants on 
   anticoagulation therapy, ≤ 1.5 × their baseline value) 
 
3.1.8 Participants must have a left ve ntricular ejection fraction (LVEF) ≥ 50%. 
 
3.1.9 Participants must have a QTc of ≤ 470 msec on the screening EKG. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
39 3.1.10 The effects of LY3022855 on the developi ng human fetus are unknown.  For this 
reason and because anti-cancer agents are known to be teratogenic, women of child-
bearing potential and men must agree to use adequate contraception (hormonal or 
barrier method of birth control; abstinence) prior to study entry and for the duration of 
study participation.  Should a woman become  pregnant or suspect she is pregnant 
while she or her partner is participating in this study, she should inform her treating physician immediately.  Men treated or enrolled  on this protocol must also agree to use 
adequate contraception prior to the study, fo r the duration of study participation, and 4 
months after completion of LY3022855  administration. 
 
3.1.11 Ability to understand and the willingness to sign a written informed consent document. 
 
3.1.12 Participants must have archival tumor tissu e available. Participants without archival 
tissue may be enrolled at the discre tion of the principal investigator.
 
 
3.2 Exclusion Criteria 
 
3.2.1 Participants who have had chemothera py, radiotherapy, biologic therapy, major 
surgery, or another investiga tional agent within 3 weeks (6 weeks for nitrosoureas or 
mitomycin C) prior to entering the study.  
 
3.2.2 For enrollment to the phase I portion: there is no required washout period for BRAF or MEK inhibitor therapy. 
 
3.2.3 Participants who have not recovered to ≤ CTCAE grade 1 or baseli ne from toxicity as 
a result of previous cancer treatment prior to entering the study (with the exception of 
alopecia and peripheral neuropathy which can be ≤ grade 2). 
 
3.2.4 For enrollment to the phase II portion: par ticipants who have r eceived prior BRAF or 
MEK inhibitor therapy. 
   
3.2.5 Participants with known untreated brain metastases should be excluded from this 
clinical trial because of their poor pr ognosis and because they often develop 
progressive neurologic dysf unction that would confound the evaluation of neurologic 
and other adverse events. Partic ipants with a history of brai n metastases that have been 
treated, are no longer taking co rticosteroids, and have been stable on imaging for ≥ 4 
weeks following the last date of treatment are permitted. 
 
3.2.6 History of allergic reactions attributed to compounds of similar chemical or biologic 
composition to LY3022855, vemurafenib, or cobimetinib. 
 
3.2.7 Uncontrolled intercurrent illness in cluding, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable  angina pectoris, cardiac 
arrhythmia, or psychiatric il lness/social situations that would limit compliance with 
study requirements. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
40 3.2.8 Pregnant women are excluded from this study because LY3022855  is an anti-cancer 
agent with the potential for te ratogenic or abortifacient effe cts.  Because there is an 
unknown but potential risk for adverse even ts in nursing infants secondary to 
treatment of the mother with LY3022855 , breastfeeding should be discontinued if the 
mother is treated with LY3022855.  These potential risks may also apply to the other 
agents used in this study. 
 
3.2.9 Participants with a known history of HIV are ineligible because of the potential for pharmacokinetic interactions  with LY3022855, vemurafenib, and cobimetinib with 
antiretroviral agents.  In addition, these part icipants are at increas ed risk of lethal 
infections when treated with marrow-suppres sive therapy.  Appropr iate studies will be 
undertaken in participants receiving co mbination antiretroviral therapy when 
indicated.  
 
3.2.10 Participants with a personal or fa mily history of long QT syndrome. 
 
3.2.11 Participants with a history of a sec ond primary malignancy. Exceptions include: 
patients with a history of ma lignancies that were treate d curatively and have not 
recurred within 3 years prior to study entry; resected basal and squamous cell 
carcinomas of the skin, and completely resected carcinoma in situ  of any type. 
 
3.2.12 Participants with impairment of GI function or GI disease that ma y significantly alter 
the absorption of vemurafenib and cobime tinib in the opinion of the treating 
investigator (e.g., ulcerative diseases , uncontrolled nausea, vomiting, diarrhea, 
malabsorption syndrome, small bowel resection). 
 
3.2.13 Participants who are unable to sw allow or retain oral medication. 
 
3.2.14 Participants that require co-administration of strong or moderate CYP3A inhibitors, as 
these medications may alter vemurafenib and cobimetinib concentrations. 
 
3.2.15 Participants who require tr eatment with medications th at are strong or moderate 
CYP3A inducers, as these medications may alter the concentration of cobimetinib. 
 
3.2.16 Participants with evidence of  retinal pathology on ophthalm ologic examination that is 
considered a risk factor for neurosenso ry retinal detachment/central serous 
chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular 
degeneration. 
 
3.3 
Inclusion of Women and Minorities 
 
Both men and women of all races and ethni c groups are eligible for this trial. 
  
4. 
REGISTRATION PROCEDURES 
  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
41 4.1 General Guidelines for DF/HCC Institutions 
 
Institutions will register eligible participants in  the Clinical Trials Management System (CTMS) 
OnCore. Registrations must occur prior to the initiation of protoc ol therapy. Any participant not 
registered to the protocol before protocol ther apy begins will be cons idered ineligible and 
registration will be denied.  An investigator will confirm eligibility criteria  and a member of the study team will complete the 
protocol-specific elig ibility checklist. 
 Following registration, participants may begin protocol therapy. Issu es that would cause 
treatment delays should be discussed with the Overall Principal Inve stigator (PI). If  a participant 
does not receive protocol thera py following registration, the part icipant’s registration on the 
study must be canceled. Registration cancellations must  be made in OnCore as soon as possible.  
 
4.2 
Registration Process for DF/HCC Institutions 
 
DF/HCC Standard Operating Procedure for Human Subject Research Titled Subject Protocol 
Registration (SOP #: REGIST-101) must be followed.   
 
4.3 General Guidelines for Ot her Investigative Sites 
 Not Applicable.  
 
4.4 
Registration Process for Other Investigative Sites 
 
Not Applicable.  
5. 
TREATMENT PLAN 
 5.1 
Treatment Regimen 
 
The starting dose for the phase I portion of the trial will be dose level 1: LY3022855 50 mg IV 
weekly, vemurafenib 960 mg by mouth twice per day (BID), a nd cobimetinib 60 mg by mouth 
once daily on days 1-21 of the cycle. Th e dose escalation scheme is depicted in Table 10 . One 
cycle is defined as 28 consecutive days. Treatment will be administered on an outpatient basis.  
Reported adverse events and potential risks are described in Section 7.  Appropriate dose 
modifications are described in 6.3.  No investigational or commercial agents or therapies other 
than those described below may be administered with the intent to treat the participant's 
malignancy, with the exception of palliative radia tion therapy or surgical resection to non-target 
lesions with prior permission from the principa l investigator. Bisphosphonate use is permitted. 
  
Table 10: Phase I Dose Escalation Schedule 
Dose Level Dose 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
42 LY3022855 Vemurafenib Cobimetinib 
1 (Starting Dose Level) 50 mg IV weekly 960 mg BID 60 mg daily (taken 
on days 1-21) 
2  75 mg IV weekly 960 mg BID 60 mg daily (taken 
on days 1-21) 
3 100 mg IV weekly 960 mg BID 60 mg daily (taken 
on days 1-21) 
 
 
Three patients will be enrolled to dose level 1. The maximum dose of LY3022855 to be 
evaluated in the triplet combination will not exceed the recommended phase 2 flat dose of singe-
agent LY3022855. Enrollment to the dose level can o ccur in parallel with  no observation period 
or delay between the start of therapy for each  enrolled patient. The patients will be observed 
during the first cycle of therapy for toxicity consistent with a dose-limiting toxicity (DLT) definition, located in 5.4.    
 Dose escalation will proceed in a standard 3+3 fashion according to the scheme in Table 11. 
 
Table 11: Phase I Dose Esca lation Decision Criteria 
Number of Participants with DLT 
at a Given Dose Level Escalation Decision Rule 
0 out of 3 Enter 3 participan ts at the next dose level. 
≥ 2 Dose escalation will be st opped.  This dose level will be 
declared the maximally administered dose (highest dose administered).  Three (3) a dditional participants will be 
entered at the next lowe st dose level if only 3 
participants were treated previously at that dose. 
1 out of 3 Enter at least 3 more participants at this dose level. 
 If 0 of these 3 participants experience DLT, proceed to the next dose level. 
 If 1 or more of this group suffer DLT, then dose escalation is stopped, and this dose is declared the maximally administered dose.  Three (3) additional participants will be entered at the next lowest dose level if only 3 participants were treated previously at 
that dose. 
≤ 1 out of 6 at highest dose level 
below the maximally administered 
dose This is generally the RP2D. At least 6 participants must be entered at the RP2D. 
 The maximally administered dose (MAD) of the study medications will be defined as the dose 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
43 level where at least two participan ts develop toxicities consistent  with a DLT definition. In this 
situation, the dose level immediately below the M AD will be defined as the MTD. In the event 
that dose level 1 is found to be intolerable (with either 2/3 or ≥ 2/6 patients experiencing a DLT), 
the trial will be discontinued. In the situation where none  of the dose levels have ≥ 2 DLTs, the 
MTD will be the highest dose administered (i.e. dose level 3). The MTD will be defined in a 
minimum of six patients.  In the event that dose level 3 is found tolerable (with ≤  1 of 6 participants  experiencing DLT); 
subsequent higher dose levels may be explored following a full protocol amendment as long as 
the LY3022855 dose does not exceed the identif ied RP2D of LY3022855 single-agent therapy. 
Upon declaring the MTD, the Overall Principal I nvestigator will review safety data generated 
during the phase 1 portion of the trial to decide the RP2D of the combination. This review will 
include a review of the DLTs that occurred among the dose levels  in conjunction wi th toxicities 
experienced among participants beyond the DLT time frame. Once the RP2D has been defined, 
the phase II portion of the tria l will begin with enrollment of 25 patients with either BRAF 
V600E or V600K mutant melanoma. Patients enrolli ng into the phase II portion of the trial will 
be treated at the RP2D for the combination id entified during the phase I portion of the study. 
 Patients enrolled to the phase I dose escalation po rtion of the trial will  be required to have 
received at least 75 perc ent of their doses of vemurafenib a nd cobimetinib, and must complete at 
least three of the four LY3022855 infusions during th e first cycle to be c onsidered evaluable for 
DLT purposes. Patients who do not meet these para meters during cycle 1 for reasons other than 
toxicity (for example, withdraw al of consent for participation on the trial, or rapid disease 
progression and subsequent removal from the trial) will be replaced.  Participants will be requested to maintain a study  medication diary that will indicate each dose of 
oral medication taken to illustrate treatment compliance. The medication diary should be returned to appropriate research staff for review at the end of each treatment cycle. 
  
5.2 
Pre-Treatment Criteria 
 
5.2.1 Cycle 1, Day 1 
 
Patients who completed screening assessments > 72 hours prior to cycle 1 day 1 should have 
cycle 1 day 1 laboratory values th at re-meet eligibility criteria. If screening assessments were 
completed ≤ 72 hours prior to cycle 1 day 1, laboratory te sts do not need to be repeated on cycle 
1 day 1 and the screening laboratory values can be used as the cycle 1 day 1 values. 
 
5.2.2 Subsequent Cycles  
 Management of specific toxicities  considered at least possibly related to the study regimen is 
outlined in 6.1. 
 
5.3 
Agent Administration 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
44 5.3.1 LY3022855 
 
LY3022855 will be given once per week on day 1, 8, 15, and 22 of the 28 day cycle. On 
days where LY3022855, vemurafenib, and cobimetinib are all to be given, order of 
administration does not matter.   LY3022855 will be administered via IV infusion. The first infusion should be scheduled to occur over 90 minutes (± 5 minute infusion window). If no infusion-related reaction occurs, the second infusion can be schedul ed to occur over 60  minutes (±5 minute 
window). If no infusion-related reaction occurs, the third and all subsequent infusions can 
be given over 30 minutes (± 5 minute window).   Please see guidance regarding hype rsensitivity reactions belo w. In the event that the 
infusion time takes longer than the above guidance (in the setting of a LY3022855 infusion-related reaction), this wi ll not be considered to be in violation of the protocol; 
however, in all cases the infusion must be completed within 4 hours of preparation . 
The exact infusion time should be accurately recorded.
 
 
Only 0.9% normal saline should be used for dilution and post-infusion flushing of the infusion line. Post-infusion, the infusion line must be flushed with 0.9% normal saline, 
with a volume equal to or greater than the hold-up volume of the infusion line. 
 
DO NOT FREEZE AND/OR SHAKE  PREPARED LY3022855 DOSING 
SOLUTION FOR INFUSION.  
 
LY3022855 should be handled according to st andard procedures and precautions 
consistent with a cytotoxic anti-cancer drug. 
 
Hypersensitivity Reactions 
 
As with other monoclonal antibodies, infusi on-related reactions may occur during or 
following LY3022855 administration. As a precauti on, during the first cycle of treatment 
with LY3022855 patients should be monitored by the medical staff for signs and 
symptoms of an infusion-related reaction from  the start of the infusion until at least one 
hour after the end of the infu sion. Monitoring should occur in  an area where resuscitation 
equipment and other agents (e.g., epinephrine, pr ednisolone or equivalents) are available. 
After completion of the first cycle, if no infusion-related reacti ons have occurred the 
post-infusion observation period may be discontinued.  Patients will not be premedicated prior to th e first infusion of LY 3022855. In the event of 
an infusion-related reaction, institutional guidelines for managing infusion reactions 
should be followed. In the case of a grade 1 infusion-related reaction, the infusion rate 
should be decreased by 50% for the duration of  the infusion. In the event of a grade 2 
infusion-related reaction, the infusion must be stopped until resolution to ≤  grade 1; the 
infusion may then be resumed at 50% of the prior infusion rate. Note that the infusion must be completed within 4 hours of prep aration. Patients should be monitored for 
worsening of condition in case of a grade 1 or 2 infusion-related reaction. Once the 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
45 infusion rate has been reduced for a grad e 1 or 2 infusion-rela ted reaction, it is 
recommended to maintain the lower infusi on rate for all subsequent infusions.  
 
If the patient experiences a grade 1 or gr ade 2 infusion-related reaction, premedication 
should be provided prior to subsequent infusions. The exact premedication regimen will be per institutional standards and investig ator discretion, and should include use of 
diphenhydramine hydrochloride 50 mg IV (or equivalent) administered prior to the infusion.  
 
Patients who experience a ≥ grade 3 infusion-related reaction will be discontinued from 
protocol therapy. 
 
5.3.2 
Vemurafenib 
 Vemurafenib will be given as per package instructions. Vemurafenib should be taken 
orally every 12 hours. A missed dose can be ta ken up to 4 hours prior to the next dose. 
Doses that would be administered outside of that timeframe should be considered missed 
and should not be taken. Tablets should not be crushed or chewed. A vomited dose 
should not be retaken, patients should con tinue with the next scheduled dose. 
Vemurafenib can be taken with or  without food. On days where LY3022855, 
vemurafenib, and cobimetinib are all to be gi ven, order of administ ration does not matter. 
 
5.3.3 
Cobimetinib 
 
Cobimetinib will be given as per package instructions. Cobimetinib should be taken orally once daily on days 1-21 of every 28 day cy cle. For the purposes of this trial, there 
is a +/- 4 hour dosing window. Doses that w ould occur outside of this timeframe should 
be considered missed and should not be take n. Tablets should not be crushed or chewed. 
A vomited dose should not be retaken, patients should continue with the next scheduled 
dose. Cobimetinib can be taken with or without food. On days where LY3022855, 
vemurafenib, and cobimetinib are all to be gi ven, order of administ ration does not matter. 
 
 
5.4 
Definition of Dose-Limiting Toxicity (DLT)  
 
Dose-limiting toxicity is based on version 4.03 of the NCI Common Terminology Criteria for 
Adverse Events (CTCAE). DLT refers to toxi cities experienced during the first cycle of 
treatment that are possibly, probably, or defini tely related to the study medication regimen. A 
DLT will be defined as follows:  
 ≥ Grade 3 non-hematological toxicity. Exceptions will be made for: 
 Nausea, vomiting, diarrhea, or constipation that  can be controlled with appropriate care. 
Grade 3 and grade 4 nausea, vomiting, diarrhea,  or constipation should be considered a 
DLT if persisting more than 48 hours despite maximum supportive intervention. 
 Grade 3 rash or photosensitivity lasting fewer th an 8 days, or that can be controlled with 
appropriate care. Grade 3 rash  or photosensitivity should be considered a DLT if it 
persists for more than 8 days and ca nnot be managed despite maximum supportive 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
46 intervention. 
 Grade 3 thrombocytopenia with clinically significant bleeding 
 Grade 4 thrombocytopenia 
 ≥ Grade 3 febrile neutropenia 
 Grade 4 anemia 
 Holding of any study medication due to toxicity  for a period of greater than 8 consecutive 
days or two separate periods of any duration during the first cycle. 
 Any other significant toxicity deemed by the principal investigat or to be dose limiting (for 
example, any toxicity that is  at least possibly related to the study medication regimen that 
results in the withdrawal of the pa tient from the study during cycle 1). 
 
Management and dose modifications associated w ith the above adverse events are outlined in 
6.1, 6.2, and 6.3.  
5.5 
General Concomitant Medication and Supportive Care Guidelines 
 
Investigators should use appropr iate supportive medications to address toxicities that arise 
during the study, including but not limited to an tiemetics, antidiarrh eals, and blood product 
transfusion.  Photosensitivity has occurred with use of both vemurafenib and cobimetinib. Patients on trial 
should be advised to avoid sun exposure, wear  protective clothing, and use a broad-spectrum 
UVA/UVB sunscreen and lip balm (SPF ≥ 30) when outdoors. 
 
5.5.1 
LY3022855 Guidelines  
No formal drug interaction studies have been performed with LY3022855. 
 
5.5.2 Vemurafenib Guidelines 
 
CYP3A4 Inhibitors or Indu cers: Vemurafenib is a subs trate of CYP3A4 based on in vitro  
data; therefore, co-administr ation of strong CYP3A4 inhib itors or inducers may alter 
vemurafenib concentrations. Co-administr ation of strong CYP3A4 inhibitors is 
prohibited (e.g., ketoconazole, itraconazole , clarithromycin, atazanavir, nefazodone, 
saquinavir, telithromycin, ritonavir, i ndinavir, nelfinavir, voriconazole).  
 Concurrent use of strong or moderate CYP3 A inducers is prohibited at any point during 
the trial due to their effects on cobimetin ib (e.g., phenytoin, carbamazepine, rifampin, 
rifabutin, rifapentin e, phenobarbital). 
 CYP1A2 Substrates: Concomitant use of vemurafenib with drugs with a narrow 
therapeutic window that are predominantly metabolized by CYP1A2 is not recommended 
as vemurafenib may increase concentrations of  CYP1A2 substrates. If co-administration 
cannot be avoided, monitor closely for toxi cities and consider a dose reduction of 
concomitant CYP1A2 substrates.  P-gp Substrates: Co-administration of ve murafenib with digoxin, a sensitive P-gp 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
47 substrate, increased digoxin systemic exposure by 1.8-fold. Avoid concurrent use of P-gp 
substrates known to have narrow therapeuti c indices. If use of these medications is 
unavoidable, consider dose reduction of P-gp substrates with narrow therapeutic indices. 
 
Concentration-dependent QT prolongation occurred in an uncontrolled, open-label 
vemurafenib QT substudy in previously treated patients with BRAF  V600E mutation-
positive metastatic melanoma. Patients that  require medications that are known to 
prolong the QTc interval should be changed to alternative drugs whenever possible. If in 
the opinion of the treating inve stigator, co-administration cannot be avoided, patients 
should be closely monitored for QT prolongation.  
5.5.3 
Cobimetinib Guidelines 
 
CYP3A Inducers: Co-administration of cobi metinib with a strong CYP3A inducer may 
decrease cobimetinib systemic exposure by more than 80% and reduce its efficacy. For 
this reason, concurrent use of  strong or moderate CYP3A inducers is prohibited at any 
point during the trial (medica tions including but not limited to phenytoin, carbamazepine, 
efavirenz, rifampin, and St. John’s Wort).  CYP3A Inhibitors: Co-administration of cobimetinib with  itraconazole (a strong 
CYP3A4 inhibitor) increased  cobimetinib systemic exposure by 6.7-fold. During the 
phase I portion of the trial, co-administration of strong or moderate CYP3A inhibitors is 
prohibited. Following the phase I portion of the trial, avoid concurrent use of cobimetinib 
and strong or moderate CYP3A inhibitors wher e possible. If concur rent short term (14 
days or less) use of moderate CYP3A inhi bitors including cert ain antibiotics (e.g., 
erythromycin, ciprofloxacin) is unavoidable  for patients who are taking cobimetinib 60 
mg, reduce cobimetinib dose to 20 mg. After discontinua tion of a moderate CYP3A 
inhibitor, resume cobimetinib at the previous dose. Use an  alternative to a strong or 
moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib. 
  
5.6 
Criteria for Taking a Partic ipant Off Protocol Therapy 
 
Duration of therapy will depend on individual re sponse, evidence of disease progression and 
tolerance. In the absence of treatment delays due to adverse event(s), treatment may continue 
indefinitely or until  one of the following criteria applies: 
 
 Disease progression, unless the patient is deri ving clinical benefit as agreed upon with 
the principal investigator 
 
 Intercurrent illness that prevents further administration of treatment 
 
 Unacceptable adverse event(s) including those described in 5.4 and 6.1 
 
 Participant demonstrates an inability or  unwillingness to comply with the oral 
medication regimen and/or documentation requirements 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
48  Participant decides to withdraw  from the protocol therapy 
 
 General or specific changes in the participant's condition render the participant 
unacceptable for further treatment in the judgment of the treating investigator 
 Participants will be removed from the protocol th erapy when any of these criteria apply.  The 
reason for removal from protocol therapy, and th e date the participant was removed, must be 
documented in the case report form (CRF). Altern ative care options will be discussed with the 
participant.  For Centralized Subject Registra tions, the research team submits a completed Off Treatment 
form to ODQ when a participant comes off study. This form can be found on the ODQ website or obtained from the ODQ registration staff.  
 For Decentralized Subject Registrations, the research team update s the relevant Off Treatment  
information in OnCore.   In the event of unusual or life- threatening complications, treating investigators must immediately 
notify the Overall PI, Dr. Elizabeth Buchbinder at DFCI pager number 40221.  
  
5.7 
Duration of Follow Up 
 
Participants will be followed until death after removal from protoc ol therapy. This follow up will 
be performed by review of the medical record, contact with care provi ders, and/or telephone 
contact as needed every 3-4 months. 
  
5.8 
Criteria for Taking a Participant Off Study 
 
Participants will be removed from study wh en any of the following criteria apply: 
 Lost to follow-up 
 Withdrawal of consent for data submission 
 Death 
 
The reason for taking a participant off study, and th e date the participant was removed, must be 
documented in the case report form (CRF).  For Centralized Subject Registra tions, the research team submits a completed Off Study form to 
ODQ when a participant comes off study. This  form can be found on the ODQ website or 
obtained from the ODQ re gistration staff.  
 For Decentralized Subject Registrations, the re search team updates the relevant Off Study 
information in OnCore.    
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
49 6. DOSING DELAYS/DOSE MODIFICATIONS 
 
Dose delays and modifications will be made as indicated in the following table. The descriptions 
and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 will be util ized for dose delays and dose modifications. A copy of the 
CTCAE version 4.03 can be downloa ded from the CTEP website: 
 http://ctep.cancer.gov/protocolDevelopment/electroni c_applications/ctc.htm .  
 
6.1 Specific Toxicity Management 
 
Dose delays and modifications due to toxicity  considered at least possibly related to LY3022855, 
vemurafenib, and/or cobimetinib will be made as indicated in the following tables. Please also see 6.2 and 6.3 for further guidance on allowed treatme nt delays and dose modifications: 
 
Table 12: Management of Elevated AST/ALT 
AST (SGOT) and/or ALT (SGPT) Increase Medication Management 
≤ Grade 2 No change. 
Grade 3, increase lasting less than 8 days 
without evidence of other hepatic injury Hold study medications until resolution to ≤ 
grade 1 or baseline. Resume study medications at the same dose level. 
Grade 3, increase lasting 8 or more days 
without evidence of other hepatic injury -OR- Grade 4, without evidence of other hepatic 
injury  Hold study medications until resolution to ≤ 
grade 1; resume study medications with one 
dose level reduction. 
≥ Grade 3, with evidence of other hepatic 
injury Discontinue protocol therapy. 
 Liver transaminase elevations ha ve been associated with all th ree study medications in previous 
clinical trials. Patients should be monitored for in creases in their liver f unction tests and for other 
signs of possible hepatic injury as clinically a ppropriate and as indicated  in the Study Calendar –
Table 23 . 
 
Table 13: Management of Neutropenia 
Neutrophil Count Decrease Medication Management 
≤ Grade 2 No change. 
Grade 3, no associated fever or infection 
-OR- Grade 4, decrease lasting less than 8 
consecutive days Hold study medications until recovery to ≤  
grade 2. Upon recovery, restart at the same dose level. 
≥ Grade 3, associated with a fever or 
infection -OR- Grade 4, decrease lasting 8 or more 
consecutive days  Hold study medications until recovery to ≤  
grade 2. Upon recovery, resume with one dose level reduction. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
50  
Table 14: Management of Thrombocytopenia 
Platelet Count Decrease Medication Management 
≤ Grade 2 No change. 
Grade 3, no clinically significant bleeding 
 Hold study medications until recovery to ≤  
grade 2. Upon recovery, restart at the same 
dose level. 
Grade 3, associated with clinically significant 
bleeding 
-OR- 
Grade 4 Hold study medications until recovery to ≤  
grade 2. Upon recovery, resume with one dose 
level reduction. 
 
 
Table 15: Management of Rash or Photosensitivity 
Rash or Photosensitivity Medication Management 
≤ Grade 2 No change.* Implement appropriate supportive care (e.g., topical or oral antibiotics or steroids, 
use of protective clothing/sunscreen).  
Grade 3, not optimally managed or lasting 
fewer than 8 consecutive days  Implement appropriate supportive care (e.g., topical or oral antibio tics or steroids). Hold 
study medications until recovery to ≤ grade 2. 
Upon recovery, restart at the same dose level. 
Grade 3, optimally managed or lasting 8 or 
more consecutive days -OR- Grade 4 Hold study medications until recovery to ≤  
grade 2. Upon recovery, resume with one dose level reduction. 
*If a patient is experiencing into lerable grade 2 rash or photosensi tivity despite optimal medical 
management, their study medicati on may be held at the treati ng investigator’s discretion. Upon 
resolution to grade 1 or baseline, the study medication can be dose reduced at the treating 
investigator’s discretion.  
  
Table 16: Management of QTc Increase (Associated with Vemurafenib) 
QTc Interval Prolonged Vemurafenib Management 
≤ Grade 2 No change. 
Grade 3, increase is ≤ 60 msec from pre-
treatment value  Hold vemurafenib until recovery to ≤ grade 2. 
Upon recovery, restart with one dose level reduction. 
Grade 3, increase is > 60 msec from pre-
treatment value -OR- Grade 4 Discontinue vemurafenib. 
  
Table 17: Management of Nausea 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
51 Nausea Medication Management 
≤ Grade 2 No change.* Implement appropriate supportive 
care (e.g., antiemetics) as clinically indicated. 
Grade 3, not optimally managed  Hold study medication and implement appropriate supportive care (including 
antiemetics and IV hydration if indicated). Upon resolution to ≤ grade 2, resume study 
medication at the same dose level. 
≥ Grade 3, optimally managed 
-OR- Grade 4  Hold study medication until resolution to ≤  
grade 2; resume study medication with one dose level reduction if ≥ grade 3 nausea 
persisted for more than 48 hours despite maximum supportive intervention. 
*If a patient is experiencing intolerable grade 2 nausea desp ite optimal medical management, 
their study medication may be he ld at the treating investigator’s  discretion. Upon resolution to 
grade 1 or baseline, the study medication can be dose reduced at the treating investigator’s 
discretion. 
  
Table 18: Management of Vomiting 
Vomiting Medication Management 
≤ Grade 2 No change.* Implement appropriate supportive care (e.g., antiemetics) as clinically indicated. 
Grade 3, not optimally managed  Hold study medication and implement appropriate supportive care (including 
antiemetics and IV hydration if indicated). 
Upon resolution to ≤ grade 1, resume study 
medication at the same dose level. 
≥ Grade 3, optimally managed 
-OR- 
Grade 4  Hold study medication until resolution to ≤  
grade 1; resume study medication with one dose level reduction if ≥ grade 3 vomiting 
persisted for more than 48 hours despite maximum supportive intervention. 
*If a patient is experiencing in tolerable grade 2 vomiting desp ite optimal medical management, 
their study medication may be he ld at the treating investigator’s  discretion. Upon resolution to 
grade 1 or baseline, the study medication may be  dose reduced at the treating investigator’s 
discretion. 
   
Table 19: Management of Diarrhea 
Diarrhea Medication Management 
≤ Grade 2 No change.* Implement appropriate supportive 
care (e.g., antidiarrheals) as clinically 
indicated. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
52 Diarrhea Medication Management 
Grade 3, not optimally managed  Hold study medication and implement 
appropriate supportive care (including 
antidiarrheals and IV hydration if indicated). Upon resolution to ≤ grade 1, resume study 
medication at the same dose level. 
≥ Grade 3, optimally managed 
-OR- Grade 4 Hold study medication until resolution to ≤  
grade 1; resume study medication with one dose level reduction if ≥ grade 3 diarrhea 
persisted for more than 48 hours despite maximum supportive intervention. 
*If a patient is experiencing in tolerable grade 2 diarrhea desp ite optimal medical management, 
their study medication may be he ld at the treating investigator’s  discretion. Upon resolution to 
grade 1 or baseline, the study medication may be  dose reduced at the treating investigator’s 
discretion. 
  
Table 20: Management of Constipation 
Constipation Medication Management 
≤ Grade 2 No change.* Implement appropriate supportive care (e.g., laxatives) as c linically indicated. 
Grade 3, not optimally managed  Hold study medication and implement appropriate supportive care (including 
laxatives and enemas if indicated). Upon 
resolution to ≤ grade 2, resume study 
medication at the same dose level. 
≥ Grade 3, optimally managed 
-OR- Grade 4  Hold study medication until resolution to ≤  
grade 2; resume study medication with one dose level reduction if ≥ grade 3 constipation 
persisted for more than 48 hours despite maximum supportive intervention. 
*If a patient is experiencing intolerable grade 2 constipa tion despite optimal medical 
management, their study medicati on may be held at the treati ng investigator’s discretion. Upon 
resolution to grade 1 or baseline, the study medication may be dose reduced at the treating 
investigator’s discretion. 
  
Table 21: Management of Other Toxicity 
Other Toxicity Medication Management 
≤ Grade 2 No change.*§  
≥ Grade 3 Hold study medication. Upon resolution to ≤ 
grade 2, resume study medication with one dose level reduction. ** 
*If a patient is experiencing into lerable grade 2 toxicity, their st udy medication may be held at 
the treating investigator’s disc retion. Upon resolution to grade 1 or baseline, the study 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
53 medication can be dose reduced at th e treating investigator’s discretion. 
**Patients who experience a ≥ grade 3 infusion-related reacti on should be discontinued from 
protocol therapy.  
§If a patient is experiencing a new grade 2 or greater increase in CPK, both urine and serum 
myoglobin laboratory tests should be performed. Additional tests may also be performed or 
repeated at the treating in vestigator’s discretion.   
  
6.2 
Treatment Delays 
 
The study medications may be held for toxicity fo r up to four weeks before the participant must 
be removed from the study. Exceptions to this  requirement are possibl e should the principal 
investigator agree that the patient may continue despite the length of time off drug.  
 Study medications may be held independently of each other if toxicity is felt by the treating 
investigator to be attributed to  one or two of the three medicat ions (e.g., a patient may continue 
to receive their LY3022855 on schedule while holdi ng their vemurafenib and/or cobimetinib). 
 If the study medication(s) is/are  placed on hold for toxicity, the counting of cycle days and 
assessment schedule will continue without inte rruption. For example, a patient who does not 
receive their cycle 2 day 15 infusion of LY3022855 due  to toxicity will proc eed with their next 
scheduled infusion and visit (cyc le 2 day 22). Additional interim visits will be conducted as 
clinically necessary to manage toxicity. The cycle will not restart for dosing delays due to 
toxicity. Exceptions to this are possible for significant treatment delays ( ≥ 2 weeks) after a 
discussion with the principal inve stigator. If an exception is ma de to restart the cycle for a 
participant in the phase II portion of the trial, tumor evaluations should continue as previously 
scheduled (tumor evaluations  should not be delayed). 
  
6.3 
Dose Modifications 
 
The first dose reduction for any toxicity mu st include a reduction in LY3022855. Further dose 
reductions will be based on the offending medication(s) according to the schedule outlined in Table 22 . In the event the trea ting investigator feels all three medications are responsible for the 
toxicity, all medications can be reduced. Dose reductions below 25 mg once per week of 
LY3022855 will not be permitted. Reductions below 480 mg BID of vemurafenib or 20 mg daily 
of cobimetinib will not be permitted.   A maximum of two dose reductions will be allowed with any one of the medications. If a patient 
requires more than two dose reductions with a ny one of the study medications, they should be 
discontinued from protocol th erapy. Exceptions are possible in  the event a patient is not 
tolerating the vemurafenib and/or cobimetinib de spite maximal dose reductions but is deriving 
clinical benefit. In this circumstance, a patien t may be allowed to cont inue on protocol therapy 
and receive LY3022855 either alone or  in combination with just the vemurafenib or cobimetinib 
if agreed upon with the principal investigator.  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
54 Patients undergoing dose reductions for t oxicities may not be re-escalated. 
 
Participants enrolled to the phase I portion of  the trial may undergo intra-patient dose escalation 
if subsequent higher dose levels are proven safe as  per the guidelines in 5.1 and 5.4. Participants 
may only undergo dose escalati ons to a dose level where ≤  1 DLT have been observed among 6 
patients, two dose levels below a dose level wher e < 1 out of 3 patients have experienced DLTs, 
or the dose level that has been declared th e RP2D. Under no circumstances may a patient 
escalate to a dose level above the MTD. Patients mu st have been on study for at least two cycles 
with no DLTs or DLT-equivalent toxici ty to be eligible for dose escalation. 
  
Table 22: Dose Modifications 
Original Dose Level LY3022855 
Reduction Vemurafenib 
Reduction* Cobimetinib 
Reduction* 
1 1st Reduction: 25 mg 
weekly 1st Reduction: 720 mg 
BID 1st Reduction: 40 mg 
once daily 
2nd Reduction: 
Discontinue protocol 
therapy 2nd Reduction: 480 
mg BID 2nd Reduction: 20 mg 
once daily 
2 1st Reduction: 50 mg 
weekly 2nd Reduction: 720 
mg BID 1st Reduction: 40 mg 
once daily 
2nd Reduction: 25 mg 
weekly 2nd Reduction: 480 
mg BID 2nd Reduction: 20 mg 
once daily 
3 1st Reduction: 75 mg 
weekly 1st Reduction: 720 mg 
BID 1st Reduction: 40 mg 
once daily 
2nd Reduction: 50 mg 
weekly 2nd Reduction: 480 
mg BID 2nd Reduction: 20 mg 
once daily 
*: Vemurafenib and cobimetinib may be redu ced as per the FDA prescribing information 
  
6.4 
Overdose management 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
55 There are no known antidotes fo r over-dosage of LY3022855, vemu rafenib, or cobimetinib. In 
the case of suspected overdose, monitor hematologic parameters, serum chemistry, vital signs, 
cardiac function, and provide supportive care as necessary.   
7. 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of reported and/or potential AEs ( 7.1) and the characteristic s of an observed AE 
(7.2 and 7.3) will determine whether the even t requires expedited reporting in addition  to 
routine reporting.  
 
7.1 Expected Toxicities 
 Please refer to the FDA prescribing information for vemurafenib and cobimetinib, along with the 
IB for LY3022855 for the most comprehensive in formation regarding expected toxicities 
associated with treatment.  Reasonably anticipated serious adverse events fo r patients with advanced melanoma who receive 
LY3022855 include: 
 Fatigue 
 Nausea/vomiting/anorexia 
 Diarrhea 
 Elevation of hepatic transaminases 
 Increases in LDH 
 Increases in blood creatine phosphokinase 
 Lymphopenia  
Fatigue has been the most frequent toxici ty reported following treatment with LY3022855, 
followed by elevation in hepatic transaminases and increases in blood creatine phosphokinase 
(CPK). Increased creatinine has been the most fr equently reported AE for patients treated with 
the combination of vemurafenib and cobime tinib, followed by increased CPK, and liver 
transaminase increases. 
 Reasonably anticipated overlapping toxicities fo r the combination may include hepatotoxicity, 
CK elevations, and cardiomyopathy.  
 
7.2 
Adverse Event Characteristics 
 
 CTCAE term (AE description) and grade:  The descriptions and grading scales found 
in the revised NCI Common Terminology Criter ia for Adverse Events (CTCAE) version 
4.03 will be utilized for AE re porting.  All appropriate treatment areas should have access 
to a copy of the CTCAE version 4.03.  A copy of the CTCAE version 4.03 can be 
downloaded from the CTEP web site: http://ctep.cancer.gov/protocolDevelopment/electroni c_applications/ctc.htm . 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
56  For expedited reporting purposes only:   
- AEs for the agent(s) that are listed above should be reported only if the adverse event 
varies in nature, intensity or  frequency from the expected toxicity information which 
is provided. 
 
 Attribution  of the AE: 
- Definite – The AE is clearly related  to the study treatment. 
- Probable – The AE is likely related to the study treatment. 
- Possible – The AE may be related  to the study treatment. 
- Unlikely – The AE is doubtfully related to the study treatment. 
- Unrelated – The AE is clearly NOT related to the study treatment. 
 
7.3 Serious Adverse Events 
 
A serious adverse event (SAE) is any adverse even t during this study that results in one of the 
following outcomes:  
 Death 
 Hospitalization for greater than 24 hours 
 Prolonging an existing i npatient hospitalization 
 A life-threatening experience (tha t is, immediate risk of dying) 
 Persistent or significant disability/incapacity 
 Congenital anomaly/birth defect 
 Considered significant by the i nvestigator for any other reason 
 Previously planned (prior to signing the info rmed consent form) surgeries, and non-disease 
related elective surgeries planned during the course of the study, should not be reported as SAEs unless the underlying medical condition has worsen ed or appeared during the course of the 
study.  Preplanned hospitalizations or procedures for pree xisting conditions that are already recorded in 
the patient’s medical history at the time of st udy enrollment should not be considered SAEs. 
Hospitalization or prolongation of  hospitalization without a preci pitating clinical AE (e.g., for 
the administration of study therapy or other protocol-required pro cedure) should not be 
considered SAEs.  Important medical events that may not resu lt in death, be life-th reatening, or require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical inte rvention to prevent one of the 
outcomes listed in this definition.  Death due to disease progression sh ould not be reported as an SA E unless the investigator deems 
it to be related to the use of study drug.  Study site personnel must alert Eli Lilly of a ny SAE as soon as possible and no later than 24 
hours of the investigator and/or  institution receiving notificati on of the SAE experienced by a 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
57 patient participating in the study.  The SAE reports  are to be sent to Eli Lilly via fax at 1-866-
644-1697. 
 
7.4 Expedited Adverse Event Reporting  
 
7.4.1 Investigators must  report to the Overall PI any se rious adverse event (SAE) that 
occurs after the in itial dose of study treatment, during treatment, or within 30 days of 
the last dose of treatment on the local institutional SAE form.  
 
7.4.2 DF/HCC Expedited Reporting Guidelines 
 
Investigative sites within DF/HCC will repor t AEs directly to the DFCI Office for 
Human Research Studies (OHRS) per the DFCI IRB reporting policy.  
 
7.5 Expedited Reporting to the Food and Drug Administration (FDA) 
 
The Overall PI, as study sponsor, will be responsible for all co mmunications with the FDA. The 
Overall PI will report to the FDA, regardless of the site of occurrence, any serious adverse event 
that meets the FDA’s criteria for expedited reporting following the reporting requirements and 
timelines set by the FDA. 
 7.6 
Expedited Reporting to Hospital Risk Management 
 
Participating investigators will report to their local Risk Management office any participant 
safety reports or sentinel ev ents that require reporting acco rding to institu tional policy.  
 
7.7 Routine Adverse Event Reporting 
 
All Adverse Events must  be reported in routine study data submissions to the Overall PI on the 
toxicity case report forms.  AEs reported through expedited processes (e.g., reported to the 
IRB, FDA, etc.) must also be reporte d in routine study data submissions.  
  
8. 
PHARMACEUTICAL INFORMATION 
 
A list of the adverse events and potential risks asso ciated with the investigational or other agents 
administered in this study can be found in 7.1. 
 
8.1 LY3022855 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
58 8.1.1 Description 
 
Molecular Structure:  LY3022855 is an anti-CSF-1R r ecombinant human monoclonal 
antibody of the IgG1 class, composed of 4 polypeptide chains: 2 identical heavy ( γ) 
chains consisting of 450 amino acids each, and 2 identical light ( κ) chains consisting 
of 214 amino acids each. The heavy chain s ubunit contains 1 consensus glycosylation 
site for N-linked oligosaccharides at position N300 in the Fc region. There are no O-
linked glycosylation sites. 
 
Molecular mass:  148 kDa 
 
pH: 6.0 at a concentration of 5 mg/mL 
 
Osmolality:  293 mmol/kg 
 The LY3022855 active ingredient is an aqueous solution at a pH of approximately 6.0 
at a concentration of 5 mg/mL. The monomeric purity of LY3022855 is > 90% by size-exclusion chromatography.  LY3022855 drug product is a sterile, preservative-free injection for infusion of LY3022855 formulated in an aqueous soluti on at a concentration of 5 mg/mL (100 
mg/20 mL vial). The buffer contains 10mM histidine, 100mM glycine, 100mM 
arginine, and 0.01% polysorbate 80. LY3022855  drug product is a clear or slightly 
opalescent liquid, without visibl e particles. All excipients used for the manufacture of 
LY3022855 drug product are of pharmacopeial grade. No animal-derived components are used in the manufacture of  LY3022855 drug product excipients.  
 
8.1.2 
Form 
 
LY3022855 drug product is supplied in single-use, 20 mL nominal volume, United 
States Pharmacopeia (USP) Type I glass vials. Each vial contains 100 mg of 
LY3022855 at a concentration of 5 mg/mL in  a sterile, preservative-free solution. 
Each vial is stoppered with a coated chlo robutyl latex-free rubbe r stopper and sealed 
with an aluminum seal and a flip-off cap. 
 
8.1.3 Storage and Stability 
 
LY3022855 Drug Product 
 
The drug product must be stored under refrige ration at 2°C to 8°C (36°F to 46°F) with 
protection from direct light. DO NOT FREEZE AND/OR SHAKE LY3022855 
DRUG PRODUCT. Stability studies have demonstrated that the drug product can withstand transient excursion to room te mperature without adverse effect; however, 
storage at this temperat ure is not recommended. 
 
LY3022855 Prepared Dosing Solution for Infusion 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
59 Chemical and physical in-use stabilit y for the prepared LY3022855 dosing solution 
has been demonstrated for up to 24 hours below 25°C (77°F). However, it is 
recommended that the prepared dosing solution be used immediately in order to minimize the risk of microbial contamination. If not used immediately, the prepared LY3022855 dosing solution should be stored und er refrigeration at 2°C to 8°C (36°F 
to 46°F) for no longer than 24 hours. If th e prepared solution is held at room 
temperature (below 25°C [77°F]) it must be used within 4 hours. Store protected from 
light. Brief exposure to ambient light is acceptable while preparation and 
administration is taking place. DO NOT FREEZE AND/OR SHAKE  PREPARED 
LY3022855 DOSING SOLUTI ON FOR INFUSION.  
 
8.1.4 
Compatibility  
The following have been found to be compatible for LY3022855 drug product infusion: 
 A polyethylene-lined PVC infusion se t with a 0.22-µm downstream high-
pressure, protein-sparing in-line filter made of polyethersulfone of 10-cm
2 
surface area 
 A PVC (with di(2-ethylhexyl)phthalate) infusion set with a 0.2-µm protein-
sparing filter made of polyethersulfone of 4.2-cm2 surface area 
 A polyethylene-lined PVC infusion set with a 0.2-µm protei n-sparing in-line 
filter made of polyethersulfone of 10-cm2 surface area 
 A polyurethane infusion set with a 0.2-µm protein-sparing in-line filter made 
of polyethersulfone of 10-cm2 surface area 
 A polybutadiene tubing with 0.2-µm in-lin e filter made of polysulfone of 9-
cm2 surface area 
 
Only 0.9% normal saline should be used for dilution and post infusion flushing of the 
infusion line. 
 
8.1.5 Handling 
 
Qualified personnel, familiar with pro cedures that minimize undue exposure to 
themselves and the environment, should undertake the preparation, handling, and safe 
disposal of the chemotherapeutic agent in a self-contained and prot ective environment.  
 
8.1.6 Availability 
 
LY3022855 is an investigational agent that w ill be supplied by Eli Lilly and Company. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
60  
8.1.7 Preparation 
 
The dose of LY3022855 should be aseptically w ithdrawn from the vi al and transferred 
to a sterile IV container. LY3022855 is comp atible with infusion containers composed 
of polyolefin, polyvinyl chloride (PVC), et hylene vinyl acetate, and evacuated glass 
(USP Type II or local equivalent). An infusion bag composed of polyolefin, 
polypropylene, and polyethylene prefilled with 0.9% sodium chloride injection, such 
as AVIVA, may also be used.  
 To administer using pre-filled IV infusion containers: 
Calculate the respective dos e and remove the correspond ing volume of 0.9% normal 
saline from the prefilled 250 mL containe r of the correct composition. Aseptically 
transfer the calculated dose  of LY3022855 drug product to th e container to bring the 
final volume in the container back to 250 mL . Gently invert the container to mix. 
 
To administer using empty IV infusion containers: 
Aseptically transfer the ca lculated dose of LY3022855 dr ug product into an empty IV 
container of the correct composition and add a sufficient quantity of sterile normal 
saline (0.9% weight/volume) to the contai ner to bring the total volume to 250 mL. 
Gently invert the container to mix.  For dose volumes greater than 250 mL, the addition of sterile normal saline is not 
required. Only 0.9% normal saline should be used for dilution and post infusion flushing of infusion line. Post infusion, th e infusion line must be flushed with 0.9% 
normal saline, with a volume equal to or greater than the hold-up volume of the 
infusion line.  Different lot numbers of LY3022855 must not be mixed in a single infusion
. 
 
 
8.1.8 Administration 
 
LY3022855 will be given once per week on da y 1, 8, 15, and 22 of the 28 day cycle. 
On days where LY3022855, vemurafenib, and cobimetinib are all to be given, order of 
administration does not matter.  
 
LY3022855 will be administered via IV infusion. The first infusion should be scheduled to occur over 90 minutes (± 5 minute infusion window). If no infusion-
related reaction occurs, the s econd infusion can be scheduled to occur over 60 minutes 
(±5 minute window). If no infusion-relate d reaction occurs, the third and all 
subsequent infusions can be given over 30 minutes (± 5 minute window).  
 
Only 0.9% normal saline should be used for dilution and post-infusion flushing of the infusion line. Post-infusion, the infusion line must be flushed with 0.9% normal saline, 
with a volume equal to or greater than the hold-up volume of the infusion line. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
61 DO NOT FREEZE AND/OR SHAKE  PREPARED LY3022855 DOSING 
SOLUTION FOR INFUSION.  
 
LY3022855 should be handled according to st andard procedures and precautions 
consistent with a cytotoxic anti-cancer drug.  
8.1.9 
Ordering 
 
Drug supply will be ordered from Eli Lilly and Company by site pharmacy personnel. 
 
8.1.10 Accountability 
 
The investigator, or a respons ible party designated by the investigator, should maintain 
a careful record of the inventory and di sposition of the agent using the NCI Drug 
Accountability Record Form (DARF) or another comparable drug accountability form.  (See the NCI Investigator’s Handbook for Pr ocedures for Drug Accountability and 
Storage.) 
 
8.1.11 
Destruction and Return 
 
Expired supplies of LY3022855 should be destroyed according to institutional policies. Destruction will be documented in  the Drug Accountability Record Form. At 
the end of the study, unused supplies of  LY3022855 should also be destroyed 
according to institutional policies and destruction will be documented in the Drug Accountability Record Form. 
 
8.2 
Vemurafenib 
 
8.2.1 Description 
 
Chemical Name:  propane-1-sulfonic acid {3-[5-(4-chloroph enyl)-1H-pyrrolo[2,3-
b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide 
 
Chemical Structure: 
 
 
 
Molecular Weight:  489.9 
 Molecular Formula:  C
23H18ClF 2N3O3S 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
62  
Solubility:  Insoluble in aqueous media 
 The inactive ingredients of  the tablet core are  hypromellose acetate succinate, 
croscarmellose sodium, colloidal si licon dioxide, magnesium stearate, and 
hydroxypropyl cellulose. The ingredients of the coating are  poly (vinyl alcohol), 
titanium dioxide, polyethylene glycol 3350, talc, and iron oxide red. 
 
8.2.2 
Form 
 
Vemurafenib is available as 240 mg film -coated tablets with VEM debossed on one 
side.  
8.2.3 
Storage and Stability 
 
Store at room temperature between 20°C–25°C (68°F–77°F); excursions permitted between 15°C and 30°C (59°F and 86°F), S ee USP Controlled Room Temperature. 
Store in the original containe r with the lid tightly closed. 
 
8.2.4 
Handling 
 
Qualified personnel, familiar with pro cedures that minimize undue exposure to 
themselves and the environment, should undertake the preparation, handling, and safe disposal of the chemotherapeutic agent in a self-contained and pr otective environment. 
 
8.2.5 
Availability 
 
Vemurafenib is commercially available.  
8.2.6 
Administration 
 
Vemurafenib will be given as per package instructions. Vemurafenib should be taken orally every 12 hours. A missed dose can be ta ken up to 4 hours prior to the next dose. 
Doses that would be administered outside of that timeframe should be considered 
missed and should not be taken. Tablets shoul d not be crushed or chewed. A vomited 
dose should not be retaken, patients should continue with the next scheduled dose. 
Vemurafenib can be taken with or without food. 
 
8.2.7 
Ordering 
 
Vemurafenib is commercially available.  The investigator or designated study 
personnel are responsible for maintaining dispensing records of vemurafenib per 
institutional standards. 
 
8.3 Cobimetinib 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
63 8.3.1 Description 
 
Chemical Name:  (S)-[3,4-difluoro-2-(2-fluoro- 4-iodophenylamino)phenyl] [3-
hydroxy-3-(piperidin-2-yl)azetidin -1-yl]methanone hemifumarate 
 
Chemical Structure: 
 
 
 
Molecular Weight:  1178.71 as a fumarate salt 
 
Molecular Formula:  C46H46F6I2N6O8 (2 C 21H21F3IN3O2 . C 4H4O4) 
 
The inactive ingredients of the tablet co re are microcrystalline cellulose, lactose 
monohydrate, croscarmellose sodium, magnesium  stearate. The inac tive ingredients of 
the tablet coating are  polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, 
talc. 
 
8.3.2 Form 
 
Cobimetinib is available as 20 mg wh ite, round, film-coated tablets with COB 
debossed on one side. Each 20 mg tablet contains 22 mg of cobimetinib fumarate, 
which corresponds to 20 mg of the cobimetinib free base. 
 
8.3.3 Storage and Stability 
 
Store at room temperature below 30°C (86°F). 
 
8.3.4 Handling 
 
Qualified personnel, familiar with pro cedures that minimize undue exposure to 
themselves and the environment, should undertake the preparation, handling, and safe disposal of the chemotherapeutic agent in a self-contained and pr otective environment. 
 
8.3.5 
Availability 
 
Cobimetinib is commercially available.  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
64 8.3.6 Administration 
 
Cobimetinib will be given as per package instructions. Cobimetinib should be taken 
orally once daily on days 1-21 of every 28 da y cycle. For the purposes of this trial, 
there is a +/- 4 hour dosing window. Doses that  would occur outside of this timeframe 
should be considered missed and should not be taken. Tablets shoul d not be crushed or 
chewed. A vomited dose should not be retake n, patients should continue with the next 
scheduled dose. Cobimetinib can be taken with or without food. 
 
8.3.7 Ordering 
 
Cobimetinib is commercially available. The investigator or designated study personnel are responsible for maintaining dispensing records of cobimetinib per institutional standards. 
 
 
9. 
BIOMARKER, CORRELATIVE , AND SPECIAL STUDIES 
 9.1 
Collection of Archival Tissue 
 
Archival tumor tissue will be collected on all pati ents enrolling to the trial as described in 2.6 - 
Correlative Studies. Patients who do not have archival tissue available will be allowed to enroll at the discretion of the principal investigator.  
 Depending on availability, 10 - 20 unstained slides will be collected. Less than the goal amount of tissue is acceptable if archival tissue is limited. The slide collection should be labeled with the 
protocol number and study subjec t number. Slides should be maile d to the following address for 
analysis:  
ATTN: CIO Laboratory Manager Center for Immuno-Oncology Laboratory Jimmy Fund Building Room 406 1 Jimmy Fund Way Boston, MA 02115 
   
9.2 
Exploratory Fresh Tumor Biopsies 
 
Optional fresh tumor biopsies will be obtained from  patients enrolled duri ng either phase of the 
trial, as described in 2.6 – Correlative Studies. The biopsies w ill only be obtained if the treating 
investigator believes the biopsy to  be clinically feasible and if  the patient is willing to undergo 
the biopsy procedures.   The optional on-treatment biopsy can be collected  anytime between Cycle 1 Day 15 and Cycle 2 
Day 1. An additional optional biopsy at the time of disease progression will also be offered to patients if deemed clinically feasible. Preferabl y, time of progression biopsi es should be obtained 
prior to the initiation of another ca ncer treatment. However, in the event that it is not possible to 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
65 perform the biopsy before another treatment is begun, the biopsy can be obtained up to 30 days 
after the last dose of LY3022855. 
 Core biopsy samples should be obtained for analys is. Three-to-four biopsy passes utilizing a 16-
18 gauge needle are preferable, but a 20 gauge co re needle biopsy is also acceptable. Less than 
the goal amount of tissue is ac ceptable for the biopsy procedures, and should be based upon the 
clinical judgment of the treat ing investigator and the clinic ian performing the procedure. 
 Biopsy samples should be formalin-fixed and pa raffin embedded per institutional standards. 
 Both the pre and on-treatment tumor biopsy sample s should be labeled with the protocol number 
and study subject number, and should be sent to the CIO lab for analysis: 
 
ATTN: CIO Laboratory Manager Center for Immuno-Oncology Laboratory Jimmy Fund Building Room 406 1 Jimmy Fund Way Boston, MA 02115 
 
 
9.3 
Laboratory Correl ative Studies 
 
A cell-free DNA (cfDNA) plasma sample and a circulating immune cell (CIC) sample will be 
collected at baseline (prior to the first dose of LY3022855, vemurafenib, and cobimetinib), at 
visits immediately following restaging scans (i .e., cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, 
etc.), and at the off study visit. Samples co llected on days where study medication dosing will 
occur can be collected anytime pre-dosing.   
9.3.1 
Cell-free DNA (cfDNA) and Circulating Immune Cell (CIC) Sample Collection Procedure: 
 
1. Blood samples should be labeled with the protocol number, study subject 
number, date of the draw, and the label, “cfDNA/CIC.” 
2. Draw venous blood into three 10 mL EDTA  tubes, immediately gently invert 
the tube 3-4 times. 
3. Send tubes to the CIO lab for processi ng within 6 hours of blood draw (tubes 
sent outside of this window due to sh ipping or scheduling difficulties will not 
be considered protocol violations): 
 
ATTN: CIO Laboratory Manager Center for Immuno-Oncology Laboratory Jimmy Fund Building Room 406 1 Jimmy Fund Way Boston, MA 02115 
  
10. 
STUDY CALENDAR 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
66 Baseline evaluations are to be c onducted within 14 days prior to start of protocol therapy, with 
the exception of the informed consent, echoc ardiogram, ophthalmologic exam, and baseline 
tumor imaging which may be obtained up to 28 days  prior to the start of  protocol therapy. 
 
Assessments must be performed prior to administration of any study agent.
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  67 
  
 Table 23: Study Calendar 
Pre-
StudyL Cycle 1 
Day 1 Cycle 1 Day 
8M Cycle 1 Day 
15M Cycle 1 Day 
22M Cycle 2+ 
Day 1N Cycle 2+ 
Day 8M Cycle 2+ Day 
15M Cycle 2+ Day 
22M Off 
TreatmentO Every 3 Months 
after Discontinuing 
Informed Consent X           
Archival Tumor 
Tissue CollectionA X           
Demographics X           
Medical history X           
Concurrent meds X X---------------------------------------------------------------------------------------------X X  
Physical exam X X X X X X  X  X  
Vital signsB X X X X X X X X X X  
Height X           
Weight X X X X X X X X X X  
ECOG Performance 
Status X X  X  X  X  X  
CBC w/diff, plts X X X X X X X X X X  
C-Reactive Protein (CRP) X Repeat as clinically indicated.   
PT-INR, PTT X Repeat as clinically indicated.   
Serum chemistryC X X X X X X X X X X  
EKGD X   X  X      
EchocardiogramE X     X      
Dermatologic 
Evaluation X Dermatologic evaluations to be performed to assess fo r suspicious skin lesions every 2 months while on 
vemurafenib/cobimetnib therapy or as per institutional standar ds. Evaluation can be perfor med and documented by treating 
investigator or by dermatologist. X  
Adverse event 
evaluation  X---------------------------------------------------------------------------------------------X X  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
68  Table 23: Study Calendar 
Pre-
StudyL Cycle 1 
Day 1 Cycle 1 Day 
8M Cycle 1 Day 
15M Cycle 1 Day 
22M Cycle 2+ 
Day 1N Cycle 2+ 
Day 8M Cycle 2+ Day 
15M Cycle 2+ Day 
22M Off 
TreatmentO Every 3 Months 
after Discontinuing 
Radiologic evaluation 
X CT or MRI imaging of any disease-involved  site. Radiologic measurements should be performed at the end of cycle 2 (Cycle 
2 Day 28) and at the end of every 2 cycles of treatment thereafte r (i.e., Cycle 4 Day 28, Cycle 6 Day 28, and so on). There is 
a +/- 7 day scheduling window  on imaging evaluations. X  
Serum β-HCGF X           
Ophthalmologic 
examination X To be conducted at baseline, on cycle 2 day 1, and as clinically indicated – to be done at the treating investigator’s discreti on based on 
institutional standards and the presence of symptoms.  
cfDNA SampleG  X Samples to be collected at visits immediately following restaging scan visits (i.e., cycle 3 day 1, cycle 5 day 1, 
cycle 7 day 1, etc.) X  
Plasma CIC SampleH  X Samples to be collected at visits immediately following restaging scan visits (i.e., cycle 3 day 1, cycle 5 day 1, 
cycle 7 day 1, etc.) X  
Fresh Tumor Tissue Biopsy
I    X     X  
LY3022855 Administration  X LY3022855 to be administered as described in 5.3.1.   
Vemurafenib Administration
J  X Vemurafenib to be adminis tered as described in 5.5.2 and as per institutional standards.   
Cobimetinib Administration
J  X Cobimetinib to be administered as described in 5.3.3 and as per institutional standards.   
Telephone or Care Provider Contact
K           X 
A. Participants must have archival tumor ti ssue available for enrollment. Participants without archival tissue may be enrolled at the discretion of the principal investigator. See 9.1 for further 
detail. 
B. Vital signs to include heart rate, blood pressure, te mperature, respiratory rate, and oxygen saturation (O 2 sat). 
C. Serum chemistry to include: s odium, potassium, chloride, CO 2, blood urea nitrogen (BUN), creatinine, glucose, albumin, total protein, alkaline phosphatase, total bilirubin, SGOT [AST], 
SGPT [ALT], globulin, phosphorus, magnesium, calcium, and creatinine phosphokinase (CPK).  Other tests may be ordered as clinically indicated. If a patient experiences a new grade 2 
or greater increase in CPK, a urine and serum myoglobin should also be obtained. 
D. EKG to be performed during screening, at anytime pre-dose on Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 3 day 1. EKGs to be colle cted every 3 months thereafter (i.e., Cycle 6 Day 1, 
Cycle 9 Day 1, and so on). EKGs can be pe rformed more frequently as clinically i ndicated or as per institutional standards. 
E. Echocardiogram (echo) to be performed during screening, on Cycle 2 day 1, and then every 3 cycles thereafter (i.e., Cycle 5 Day 1, Cycle 8 Day 1, and so  on). Echo can be performed 
more frequently if clinically indicated. 
F. Serum pregnancy test only required for wome n of childbearing potential. Childbearing potential defined as any female who has experienced menarche a nd who has not undergone 
successful surgical sterilization (hysterectomy, bilateral tuba l ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea >12 consecutive months; or women 
with a documented plasma follicle-stimulating hormone level >35µlU/mL). 
G. cfDNA plasma genotyping sample to be obtained anytime pre-dose on Cy cle 1 Day 1. The exact time of the sample should be recorded. Additional samples to be collected at visits 
immediately following restaging scans (i.e., cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, etc.), and at the off treatment visit. Please see 9.3.1 for more detail. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
69  Table 23: Study Calendar 
Pre-
StudyL Cycle 1 
Day 1 Cycle 1 Day 
8M Cycle 1 Day 
15M Cycle 1 Day 
22M Cycle 2+ 
Day 1N Cycle 2+ 
Day 8M Cycle 2+ Day 
15M Cycle 2+ Day 
22M Off 
TreatmentO Every 3 Months 
after Discontinuing 
H. Plasma CIC sample to be obtained anytime pre-dose on Cycle 1 Day 1. The exact time of the sample  should be recorded. Additional  samples to be collected at visits immediately 
following restaging scans (i.e., cycle 3 day 1, cycle 5 day 1, cy cle 7 day 1, etc.), and at the off study visit. Please see Sec tion 9 for more detail. 
I. Optional fresh tumor tissue biopsy to be obtained anytime between  cycle 1 day 15 and cycle 2 day 1. An additional optional biop sy at the time of disease progression may be obtained up 
to 30 days after the last dose of LY3022855. Please see 9.2 for more detail. 
J. Vemurafenib and cobimetinib to be dispensed and administered as described in 5.3.2 and 5.3.3 and as per institutional standards. 
K. Participants will be followed until death or withdrawal of consent after removal from protocol therapy for survival status only . This follow up will be perfor med by review of the medical 
record, contact with care providers, and/or telephone contact as needed every 3-4 months. 
L. Baseline evaluations are to be conducted with in 14 days prior to start of protocol th erapy, with the excep tion of the informed consent, echocardiogram, ophthalmologic exam, and baseline 
tumor imaging which may be obtained up to 28 days  prior to the start of protocol therapy. 
M. A +/- 1 day scheduling window exists to accommodate holidays, adverse weather, vacations, or other scheduling requests. 
N. The start of a subsequent cycle may be delayed by up to 7 days to allow for vacations or other scheduling requests. 
O. Off-treatment evaluation to be completed w ithin 30 days of the last dose of LY3022855.  Note: Follow up visits or other contact is required in order to identify SAEs during the 30 days 
following the end of study treatment.  
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
  70 
 11. MEASUREMENT OF EFFECT 
 
Although response is not the primary endpoint of th e phase I portion of this trial, participants 
with measurable disease will be assessed by standard criteria.  For th e purposes of this study, 
participants should be  re-evaluated every  eight  weeks.  In addition to a baseline scan, 
confirmatory scans will also be obtained not less than four weeks following initial 
documentation of an objective response.  
11.1 
Antitumor Effect – Solid Tumors 
 
For the purposes of this study, participants should be re-evaluated for response every eight weeks.  In addition to a baseli ne scan, confirmatory scans shoul d also be obtained not less than 
four weeks following initial docum entation of objective response. 
 Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluati on Criteria in Solid Tumors (RECIST) guideline (version 1.1) 
[Eur J Ca 45:228-247, 2009].  Changes in the largest di ameter (unidimensional measurement) of 
the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the 
RECIST criteria.  Participants enrolling to the phase I portion of the trial who do not have measurable disease at baseline per RECIST 1.1 guideline s may be enrolled if they have  evaluable disease. Evaluable 
disease includes non-measurable disease: sma ll lesions (longest diameter <10 mm or 
pathological lymph nodes with ≥10 to <15 mm short axis), bone le sions, leptomeningeal disease, 
ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses that cannot be accurately measured by CT or MRI are all considered non-
measurable. For the purposes of the phase I portion of the trial a participan t who exhibits one or 
more non-measurable disease parame ters but does not meet the defi nition for measurable disease 
may be enrolled assuming that they meet the ot her eligibility requireme nts of the protocol. 
 
11.1.1 
Definitions 
 Evaluable for Target Disease response.  Only  those participants who have measurable 
disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered ev aluable for target disease response.  These 
participants will have their response classified according to the definitions stated below.  
(Note:  Participants who exhibit objective dise ase progression prior to the end of cycle 1 
will also be considered evaluable.)  Evaluable Non-Target Disease Response.  Pa rticipants who have lesions present at 
baseline that are evaluable but do not meet th e definitions of measurable disease, have 
received at least one cycle of  therapy, and have had their disease re-evaluated will be 
considered evaluable for non-target disease.   The response assessment is based on the 
presence, absence, or unequivocal progression of the lesions.  
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
71 11.1.2 Disease Parameters 
 
Measurable disease.  Measurable lesions ar e defined as those that can be accurately 
measured in at least one dimension (l ongest diameter  to be recorded) as ≥ 20 mm by 
chest x-ray or ≥10 mm with CT scan, MRI, or calipers by clinical exam.  All tumor 
measurements must be recorded in millimeters (or decimal fractions of centimeters). 
 
Note: Tumor lesions that are situated in a previously irradiated area will not be 
considered measurable.   
 Malignant lymph nodes.  To be considered pathologically enlarged and measurable, a 
lymph node must be ≥15 mm in short axis when asse ssed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and in follow-up, only 
the short axis will be measured and followed.  
Non-measurable disease.  All other lesions (or sites of disease), including small lesions 
(longest diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), 
are considered non-measurable disease.  Bone  lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, 
abdominal masses (not followed by CT or MRI), and cystic lesions are all considered non-measurable.  Note: Cystic lesions that meet the criteri a for radiographically defined simple cysts 
should not be considered as malignant lesi ons (neither measurab le nor non-measurable) 
since they are, by definition, simple cysts.  ‘Cystic lesions’ thought to repr esent cystic metastases can be considered as measurable 
lesions, if they meet the definition of m easurability described above. However, if non-
cystic lesions are present in the same partic ipant, these are preferred for selection as 
target lesions.  Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, represen tative of all involved organs, should be identified as target 
lesions and recorded and measured at baseline.  Target lesions shoul d be selected on the 
basis of their size (lesions w ith the longest diameter), be representative of all involved 
organs, but in addition should be those that lend themselves  to reproducible repeated 
measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected. A sum of the diameters (longest for non-nodal 
lesions, short axis for nodal le sions) for all target lesions will be calculated and reported 
as the baseline sum diameters. If lymph nodes ar e to be included in the sum, then only the 
short axis is added into the sum. The baseline sum diameters will be used as reference to further characterize any objective tumor regres sion in the measurable dimension of the 
disease.   Non-target lesions.  All other lesions (or sites of disease) in cluding any measurable 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
72 lesions over and above the 5 target  lesions should be identified as non-target lesions  and 
should also be recorded at baseline. Measurem ents of these lesions are not required, but 
the presence, absence, or in rare cases unequivocal progression of each should be noted 
throughout follow up.  
 
11.1.3 Methods for Evaluation of Disease 
 
All measurements should be taken and recorded in metric notation using a ruler, calipers, 
or a digital measurement tool.  All baseline ev aluations should be performed as closely as 
possible to the beginning of treatment and ne ver more than 4 weeks before the beginning 
of the treatment.  The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at ba seline and during follow-up. Imaging-based 
evaluation is preferre d to evaluation by clin ical examination unless the lesion(s) being 
followed cannot be imaged but are assessable by clinical exam.  
 Clinical lesions.  Clinical lesions will onl y be considered measurable when they are 
superficial ( e.g., skin nodules and palpable lymph nodes) and ≥10 mm in diameter as 
assessed using calipers ( e.g., skin nodules).  In the case of skin lesions, documentation by 
color photography, including a ruler to estima te the size of the lesion, is recommended.  
 Chest x-ray.   Lesions on chest x-ray are acceptable as  measurable lesions when they are 
clearly defined and surrounded by aerated lung; however, CT is preferable.  
 Conventional CT and MRI. This guideline ha s defined measurability of lesions on CT 
scan based on the assumption that CT thickness is 5mm or less. If CT scans have slice thickness greater than 5 mm, the minimum size of a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (e.g. for body scans).   
 Use of MRI remains a complex issue.  MRI ha s excellent contrast, spatial, and temporal 
resolution; however, there are many image ac quisition variables involved in MRI, which 
greatly impact image quality, lesion conspicu ity, and measurement.  Furthermore, the 
availability of MRI is vari able globally.  As with CT, if an MRI is performed, the 
technical specifications of the scanning sequences used should be optimized for the 
evaluation of the type and site of disease.  Fu rthermore, as with CT, the modality used at 
follow-up should be the same as was used at baseline and the lesions should be 
measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body 
parts, and diseases.  Ideally, the same type  of scanner should be used and the image 
acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath-hold scanning techniques, if possible. 
 FDG-PET. While FDG-PET response assessmen ts need additional study, it is sometimes 
reasonable to incorporate the use of FDG-P ET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
73 of FDG-PET imaging can be identified according to the following algorithm:  
(a) Negative FDG-PET at baseline, with a pos itive FDG-PET at follo w-up is a sign of 
PD based on a new lesion. 
(b)  No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive 
FDG-PET at follow-up corresponds to a new site  of disease confirmed by CT, this is 
PD.  If the positive FDG-PET at follow-up is  not confirmed as a new site of disease 
on CT, additional follow-up CT  scans are ne eded to determine if there is truly 
progression occurring at that site (if so, the date of PD will be the date of the initial 
abnormal FDG-PET scan).  If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the basis of the anatomic 
images, this is not PD. (c)  FDG-PET may be used to upgrade a re sponse to a CR in a manner similar to a 
biopsy in cases where a residual radiogra phic abnormality is thought to represent 
fibrosis or scarring.  The use of FD G-PET in this circumstance should be 
prospectively described in the protocol and supported by disease-specific medical 
literature for the indication.  However, it mu st be acknowledged that both approaches 
may lead to false positive CR due to  limitations of FDG-PET and biopsy 
resolution/sensitivity.  
Note:  A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake greater than twice that of the surrounding tissue on the attenuation corrected image. 
 PET-CT. At present, the low dose or attenu ation correction CT portion of a combined 
PET-CT is not always of optimal dia gnostic CT quality for use with RECIST 
measurements.  However, if the site can doc ument that the CT performed as part of a 
PET-CT is of identical diagnos tic quality to a diagnostic CT (w ith IV and oral contrast), 
then the CT portion of the PET-CT can be used for RECIST measurements and can be used interchangeably with conventional CT in accurately measuring cancer lesions over time.  Note, however, that the PET portion of the CT introduces additional data which 
may bias an investigator if it is no t routinely or seri ally performed.   
MIBG (meta-iodobenzylguanidine).The followi ng is recommended, to assure high 
quality images are obtained.  
Patient preparation: Iodides, usually SSKI (saturated solution of potassium iodide), 
are administered to reduce thyroidal accu mulation of free radioiodine, preferably 
beginning the day prior to injection and c ontinuing for 3 additional days (4 days 
total). For infants and children, one drop t.i. d. is sufficient, for adolescents 2 drops 
t.i.d., and for adults 3 drops t.i.d. Participants and/or parents are asked about exposure 
to potential interfering agents. If none is  noted, an indwelling intravenous line is 
established. The dose of MIBG is administered by slow intravenous injection over 90 
seconds.  
Images from the head to the distal  lower extremities should be obtained.  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
74 I-123MIBG scintigraphy is performed to obtain both planar and tomographic images.  
Planar: Anterior and posterior views from the top of the head to the proximal lower 
extremities are obtained for 10 minutes at  24 hours and occasionally at 48 hours 
following injection of 10  mCi/1.7 square meters of  body surface area (~150 μCi/kg, 
maximum 10 mCi). Anterior views of the distal lower extremities are adequate. A 
large field of view dual head  gamma camera with low energy collimators is preferred.  
 
SPECT: Most participants receiving I-123 MIBG also undergo SP ECT at 24 hours, 
using a single or multi-headed camera with a low energy collimator. The camera is 
rotated through 360 degrees, 120 projecti ons at 25 seconds per stop. Data are 
reconstructed using filtered ba ck projections with a Butte rworth filter and a cut off 
frequency of 0.2-0.5. SPECT/CT may be perfor med at institutions with this capacity.  
 Ultrasound. Ultrasound is not useful in assessme nt of lesion size and should not be used 
as a method of measurement. Ultrasound exam inations cannot be reproduced in their 
entirety for independent review at a later data and, because they are operator dependent, it cannot be guaranteed that the same technique  and measurements will be taken from one 
assessment to the next. If new lesions are id entified by ultrasound in  the course of the 
study, confirmation by CT or MRI is advised. If there is concern about  radiation exposure 
from CT, MRI may be used instead of CT in selected instances.  
 Endoscopy, Laparoscopy. The utilization of  these techniques for objective tumor 
evaluation is not advised. However, such tech niques may be useful to confirm complete 
pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint. 
 
Tumor markers. Tumor markers alone cannot be  used to assess response. If markers are 
initially above the upper normal limit, they must normalize for a participant to be 
considered in complete clinical response.  Specific guidelines for both CA-125 response 
(in recurrent ovarian cancer) and PSA response (in recurrent prostate  cancer) have been 
published [ JNCI  96:487-488, 2004; J Clin Oncol  17, 3461-3467, 1999; J Clin Oncol  
26:1148-1159, 2008].  In addition, the Gynecolo gic Cancer Intergroup has developed 
CA-125 progression criteria whic h are to be integrated wi th objective tumor assessment 
for use in first-line tria ls in ovarian cancer [JNCI  92:1534-1535, 2000]. 
 
Cytology, Histology. These techniques can be used to differentiate between partial 
responses (PR) and complete re sponses (CR) in rare cases ( e.g., residual lesions in tumor 
types, such as germ cell tumors, where known residual benign tumors can remain).  The cytological confirmation of the neoplastic  origin of any effusion that appears or 
worsens during treatment when the measurab le tumor has met criteria for response or 
stable disease is mandatory to differentia te between response or stable disease (an 
effusion may be a side effect of th e treatment) and progressive disease. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
75 11.1.3.1 Evaluation of Target Lesions 
 
Complete Response (CR):  Disappearance of  all target lesions.  Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to <10 
mm. 
 Partial Response (PR):  At least a 30% decreas e in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters. 
 Progressive Disease (PD):  At  least a 20% increase in th e sum of the diameters of 
target lesions, taking as reference th e smallest sum on study (this includes the 
baseline sum if that is the smallest on study) .  In addition to the relative increase of 
20%, the sum must also demonstrate an absolu te increase of at least 5 mm.  (Note:  
the appearance of one or more new lesi ons is also considered progressions). 
 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as refe rence the smallest sum diameters while on 
study. 
 
11.1.3.2 Evaluation of Non-Target Lesions 
 Complete Response (CR):  Disappearance of all non-target lesions  and normalization 
of tumor marker level.  All lymph nodes must be non-pathological in size (<10 mm 
short axis).  Note:  If tumor markers ar e initially above the upper normal limit, they must 
normalize for a patient to be consider ed in complete clinical response. 
 Non-CR/Non-PD:  Persistence of one or  more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits. 
 Progressive Disease (PD):  Appearance of one or more new lesions and/or 
unequivocal progression  of existing non-target lesions.  Unequivocal progression  
should not normally trump target lesion status .  It must be repr esentative of overall 
disease status change, not a si ngle lesion increase.     
 Although a clear progre ssion of “non-target” lesions only is exceptional, the opinion 
of the treating physician shoul d prevail in such circumstances, and the progression 
status should be confirmed at a later time by the review panel (or Principal 
Investigator). 
 11.1.3.3 
Evaluation of New Lesions 
 The finding of a new lesion should be unequi vocal (i.e. not due to difference in 
scanning technique, imaging modality, or findings thought to represent something 
other than tumor (for exampl e, some ‘new’ bone lesions may be simply healing or 
flare of pre-existing lesions). However, a lesion identified on a follow-up scan in an 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
76 anatomical location that was not scanned at baseline is considered new and will 
indicate PD. If a new lesion is equivocal  (because of small size etc.), follow-up 
evaluation will clarify if it truly represents new disease and if PD is confirmed, 
progression should be declared using the date of the initial scan on which the lesion 
was discovered.  
11.1.3.4 
Evaluation of Best Overall Response 
 The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  The patient's best 
response assignment will depend on the achievement of both measurement and confirmation criteria.  
 
Table 24: Participants with Measurable Disease ( i.e., Target Disease) 
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Overall Response when 
Confirmation is Required* 
CR CR No CR >4 wks Confirmation** 
CR Non-CR/Non-
PD No PR 
>4 wks Confirmation** CR Not evaluated No PR 
PR Non-CR/Non-
PD/not 
evaluated No PR 
SD Non-CR/Non-
PD/not 
evaluated No SD Documented at least once >4 
wks from baseline** 
PD Any Yes or No PD 
no prior SD, PR or CR Any PD*** Yes or No PD 
Any Any Yes PD 
 See RECIST 1.1 manuscript for further detail s on what is evidence of a new lesion. 
**        Only for non-randomized trials with response as primary endpoint. ***      In exceptional circumstances, unequivoc al progression in non-target lesions may be 
            accepted as disease progression. 
 
Note:  Participants with a global deteriorati on of health status re quiring discontinuation of 
treatment without objective evidence of di sease progression at that time should be 
reported as “ symptomatic deterioration.”   Every effort should be made to document the 
objective progression even after discontinuation of treatment. 
 
 
Table 25: Participants with Non-Measurable Disease ( i.e., Non-Target Disease) 
Non-Target Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No Non-CR/non-PD* 
Not all evaluated No not evaluated 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
77 Unequivocal PD Yes or No PD 
Any Yes PD 
 ‘Non-CR/non-PD’ is preferred over ‘stable dise ase’ for non-target disease since SD is 
increasingly used as an endpoint for assessmen t of efficacy in some trials so to assign 
this category when no lesions can be measured is not advised 
 
11.1.4 Duration of Response  
 
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (w hichever is first recorded) until the first 
date that recurrent or progressive disease is  objectively documented (taking as reference 
for progressive disease the smallest measuremen ts recorded since the treatment started, or 
death due to any cause. Partic ipants without events report ed are censored at the last 
disease evaluation).  Duration of overall complete response: The duration of overall CR is measured from the 
time measurement criteria are first met for CR until the first date that progressive disease is objectively documented, or death due to any cause. Participants without events 
reported are censored at the last disease evaluation.   
 Duration of stable disease:  Stable disease is measured from the start of the treatment 
until the criteria for progression are met, taki ng as reference the smallest measurements 
recorded since the treatment started, including the baseline measurements.  
 
11.1.5 Progression-Free Survival  
 
Overall Survival: Overall Survival (OS) is  defined as the time from randomization (or 
registration) to death due to any cause, or censored at date last known alive.  Progression-Free Survival: Progression-Free Survival (PFS) is define d as the time from 
randomization (or registration) to the earlier of progression or death due to any cause. 
Participants alive without disease progressi on are censored at date of last disease 
evaluation.  Time to Progression: Time to Progre ssion (TTP) is defined as the time from 
randomization (or registration) to progressi on, or censored at date of last disease 
evaluation for those wit hout progression reported. 
 
11.1.6 Response Review 
 
Evaluation of scans will be done centrally at  the DFCI using the Tumor Metrics Core.  
 
  
12. 
DATA REPORTING / REGULATORY REQUIREMENTS 
 
Adverse event lists, guidelines, and instru ctions for AE reporting can be found in 7.1 (Adverse 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
78 Events: List and Reporting Requirements). 
 
12.1 Data Reporting 
 
12.1.1 Method 
 
The ODQ will collect, manage, and perform quality checks on the data for this study. 
 
12.1.2 Responsibility for Data Submission 
  
Investigative sites within DF/HCC or DF/PCC are responsible for submitting data and/or 
data forms to the InForm application desi gned by CTRIO according to the schedule set 
by CTRIO. 
 12.2 
Data Safety Monitoring 
 
The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity and accrual data from this study. The committee is  composed of clinical specialists with 
experience in oncology and who have no direct re lationship with the study. Information that 
raises any questions about participant safety wi ll be addressed with the Overall PI and study 
team.  The DSMC will review each protocol up to four times a year or more often if required to review toxicity and accrual data. Information to be provided to the committee may include: up-to-date participant accrual; current dose level informati on; DLT information; all grade 2 or higher 
unexpected adverse events that have been report ed; summary of all deaths occurring within 30 
days of intervention for Phase I or  II protocols; for gene therapy protocols, summary of all deaths 
while being treated and during ac tive follow-up; any response info rmation; audit results, and a 
summary provided by the study team. Other information (e.g. scans, laboratory values) will be provided upon request.    
13. 
STATISTICAL CONSIDERATIONS 
 
A standard 3+3 design is planne d for the dose finding phase I portion of the trial. The phase I 
portion of the trial will require a minimum of six and a maximum of 18 patients to determine the 
MTD and RP2D. Following identific ation of the MTD and RP2D, a single-arm phase II trial will 
commence. A total of 25 patients with  metastatic melanoma harboring a BRAF  V600E or V600K 
mutation will be enrolled to the phase II portion of the trial.  
 
13.1 Study Design/Endpoints 
 Primary Endpoints: 
 
For the phase I portion of the trial: 
 
A conventional algorithm (3+3 design) will be used to identify the MTD, escalating on 0/3 or 1/6 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
79 DLTs, and de-escalating if two DLTs are encounte red. The MTD will be the highest dose level at 
which  ≤  1/6 subjects experience a DLT. If dose level 1 is discovered to be intolerable (with 2/3 
or ≥ 2/6 subjects experiencing a DLT), the tria l will be discontinued. The probabilities of 
escalation if the true but unknown DLT rate s are 10, 20, 30, 40, and 50% are 91, 71, 49, 31, and 
17%, respectively.  
 Data will be summarized using descriptive statistics for continuous variables and frequencies, percentages for discrete variables, and presented by dos e group, as appropriate.  
 
For the phase II porti on of the trial:  
 
Primary Endpoint : 
 For the phase II portion of the trial, the primary endpoint will be PFS, defi ned as the time from 
study enrollment until the identification of diseas e progression by RECIST 1.1 criteria or death. 
Patients who have not experienced an event of interest by the time of analysis will be censored at the date they are last known  to be progression-free. 
 Power is based on the Wald test of the log fa ilure rate. We assume uniform accrual for 12 
months, 12 additional months of follow-up, and a null median PFS of 10 months. A sample of 25 
subjects, with 12 observed PFS events, will have 85% power to detect an alternative median PFS of 20 months (hazard ratio = 2), The design assumes a one-sided, type-I error of 10%. The null median PFS of 10 months will be rejected if the observed median PFS is at least 14.5 months. 
 
Secondary Endpoints: 
 
Overall response rate (ORR) will be assessed by RECIST 1.1 criteria and will be graded as 
complete response, partial response, stable dise ase and progressive disease. Overall survival 
(OS) will be defined as the time from study enro llment to death from any cause. Patients who are 
alive at the time of analysis will be censored at the date of last vital status. 
 Toxicity will be assessed using the CTCAE version 4.03.  
Exploratory Endpoints: 
 
Data from correlative studies will be summari zed using descriptive st atistics. Associations 
between MAPK signaling, TAMs, and immune infiltrat es will be compared to clinical outcome 
and will be summarized by descriptive me thods and may be explored graphically. 
 Additionally, tumor DNA levels ob tained from the serial collection of cfDNA samples will be 
examined to explore whether clinical outco me correlates to fluctuations following the 
administration of LY3022855 combination therapy.  
13.2 
Sample Size, Accrual Ra te and Study Duration 
 
The planned sample size is between six and 18 patients in the phase I portion of the trial, and 25 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
80 patients in the phase II portion of  the trial, for a total of 31 to  43 patients. The planned accrual 
rate is approximately 5 patients per quarter. Up to an additional one year of follow-up will be 
required for the last participant accrued to observe  the patient’s response and survival following 
therapy, for a total study length of about four year s. Participants will be identified via targeted 
NextGen sequencing using the DFCI/BWH OncoPa nel or another CLIA-certified method for 
genotyping. 
 
 
Table 26: Accrual Targets
Ethnic Category  Sex/Gender
Females Males  Total
Hispanic or Latino 0 + 1 = 1 
Not Hispanic or Latino 15 + 27 = 42 
Ethnic Category: Total of all subjects 15  + 28  = 43  
Racial Category  
American Indian or Alaskan Native 0 + 1 = 1 
Asian 0 + 0 = 0 
Black or African American 0 + 0 = 0 
Native Hawaiian or other Pacific 
Islander 0 + 0 = 0 
White 15 + 27 = 42 
Racial Category: Total of all subjects  15  + 28  = 43  
     
 13.3 
Analysis of Primary and Secondary Endpoints 
 
The primary and secondary analyses will include all eligible patients who started assigned therapy. The phase II evaluations wi ll not include the pati ents enrolled to the phase I portion of 
this trial. The exception to this includes the plan ned analysis of toxicity data, which will include 
all patients who received study drug  regardless of eligibility.  
 Overall response rate will be pr esented with a 90% exact binomial confidence interval.  For a 
sample of size 25, the confidence interval will be no wider than 0.35.  The distributions of 
overall survival and progression -free survival will be describe d using the method of Kaplan-
Meier.  Median PFS and OS will be summarized with 90% confidence intervals estimated using 
log (-log(endpoint)) methodology. 
 
In the event that there are missing data points,  no imputation of the missing data will be 
conducted.   
13.4 
Reporting and Exclusions 
 
13.4.1 Evaluation of Toxicity 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
81 All participants will be evalua ble for toxicity from the time of their first dose of study 
medication. 
 
13.4.2 Evaluation of the Prim ary Efficacy Endpoint 
 
All eligible participants in cluded in the study will be assessed for response, even if 
there are major protocol ther apy deviations. Each particip ant should be assigned one of 
the following categories: 1) complete response,  2) partial response, 3) stable disease, 
4) progressive disease, 5) early death from  malignant disease, 6) early death from 
toxicity, 7) early death because of ot her cause, or 9) unknown (not assessable, 
insufficient data). By arbitrary conven tion, category 9 usually designates the 
"unknown" status of any type of data in a clinical database. 
 
14. PUBLICATION PLAN 
 
The results should be made public within 24 mont hs of reaching the end of the study. The end of 
the study is the time point at which the last data  items are to be reported, or after the outcome 
data are sufficiently mature for analysis, as defi ned in the section on Sample Size, Accrual Rate 
and Study Duration. If a report is pl anned to be published in a peer -reviewed journal, then that 
initial release may be an abstra ct that meets the requirements of the International Committee of 
Medical Journal Editors. A full report of the outco mes should be made public no later than three 
(3) years after the end of the study.  
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
82  
15. REFERENCES 
 
1. Siegel RL, Miller KD, Jema l A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-
30. 
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in 
melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516. 
3. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopat hologic associations 
of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246. 
4. Robert C, Karaszewska B, Schachter J, et al . Improved overall survival in melanoma with 
combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39. 
5. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-
mutated melanoma. N Engl J Med. 2014;371(20):1867-1876. 
6. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann 
Med. 1995;27(1):79-85. 
7. Sasmono RT, Oceandy D, Pollard JW, et al . A macrophage colony-stimulating factor 
receptor-green fluorescent protein transg ene is expressed throughout the mononuclear 
phagocyte system of the mouse. Blood. 2003;101(3):1155-1163. 
8. Bourette RP, Rohrschneider LR. Early events in M-CSF receptor signaling. Growth 
Factors. 2000;17(3):155-166. 
9. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in 
action. Trends Cell Biol. 2004;14(11):628-638. 
10. Lin H, Lee E, Hestir K, et al. Discover y of a cytokine and its receptor by functional 
screening of the extracellular proteome. Science. 2008;320(5877):807-811. 
11. Nowicki A, Szenajch J, Ostrowska G, et al . Impaired tumor growth in colony-stimulating 
factor 1 (CSF-1)-deficient, m acrophage-deficient op/op mouse: evidence for a role of 
CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer. 
1996;65(1):112-119. 
12. Lewis CE, Pollard JW. Distinct role  of macrophages in different tumor 
microenvironments. Cancer Res. 2006;66(2):605-612. 
13. Bingle L, Brown NJ, Lewis CE. The role of  tumour-associated macrophages in tumour 
progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254-265. 
14. Lin EY, Nguyen AV, Russell RG, Pollard JW . Colony-stimulating factor 1 promotes 
progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-740. 
15. Dubreuil P, Torrès H, Courcoul MA, Birg F,  Mannoni P. c-fms expression is a molecular 
marker of human acute myeloid leukemias. Blood. 1988;72(3):1081-1085. 
16. Kacinski BM, Scata KA, Carter D, et al . FMS (CSF-1 receptor) and CSF-1 transcripts 
and protein are expressed by human breas t carcinomas in vivo and in vitro. Oncogene. 
1991;6(6):941-952. 
17. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S. M-CSF (monocyte colony 
stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF 
mediated recruitment of tumour infiltrating monocytes? J Cell Biochem. 1992;50(4):350-
356. 
18. Kacinski BM. CSF-1 and its receptor in brea st carcinomas and neoplasms of the female 
reproductive tract. Mol Reprod Dev. 1997;46(1):71-74. 
19. Mroczko B, Groblewska M, Wereszczy ńska-Siemiatkowska U, et  al. Serum m acrophage-
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
83 colony stimulating factor levels  in colorectal cancer patient s correlate with lymph node 
metastasis and poor prognosis. Clin Chim Acta. 2007;380(1-2):208-212. 
20. Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating 
factor in peritumoral liver ti ssue is associated with poor su rvival after cu rative resection 
of hepatocellular carcinoma. J Clin Oncol. 2008;26(16):2707-2716. 
21. Scholl SM, Pallud C, Beuvon F, et al. Anti- colony-stimulating fact or-1 antibody staining 
in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates 
and prognosis. J Natl Cancer Inst. 1994;86(2):120-126. 
22. Pollard JW. Tumour-educated macrophages pr omote tumour progression and metastasis. 
Nat Rev Cancer. 2004;4(1):71-78. 
23. Guo JK, Cantley LG. Cellular main tenance and repair of the kidney. Annu Rev Physiol. 
2010;72:357-376. 
24. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. 2006;18(1):49-53. 
25. Watanabe S, Yoshimura A, Inui K, et  al. Acquisition of the monocyte/macrophage 
phenotype in human mesangial cells. J Lab Clin Med. 2001;138(3):193-199. 
26. Wang T, Papoutsi M, Wiesmann M, et al. Investigation of correlation among safety 
biomarkers in serum, histopathological examination, and toxicogenomics. Int J Toxicol. 
2011;30(3):300-312. 
27. Radi ZA, Koza-Taylor PH, Bell RR, et al. Increased serum enzyme levels associated with 
kupffer cell reduction with no signs of he patic or skeletal muscle injury. Am J Pathol. 
2011;179(1):240-247. 
28. Leek RD, Harris AL. Tumor-associat ed macrophages in breast cancer. J Mammary Gland 
Biol Neoplasia. 2002;7(2):177-189. 
29. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate 
resistance to RAF inhibi tors through HGF secretion. Nature. 2012;487(7408):500-504. 
30. Wilson TR, Fridlyand J, Yan Y, et al. Wi despread potential fo r growth-factor-driven 
resistance to anticancer  kinase inhibitors. Nature. 2012;487(7408):505-509. 
31. Mok S, Tsoi J, Koya RC, et al. Inhibiti on of colony stimula ting factor-1 receptor 
improves antitumor efficacy of BRAF inhibition. BMC Cancer. 2015;15:356. 
32. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. 
Immunity. 2014;41(1):49-61. 
33. Wang T, Xiao M, Ge Y, et al. BRAF I nhibition Stimulates Melanoma-Associated 
Macrophages to Drive Tumor Growth. Clin Cancer Res. 2015;21(7):1652-1664. 
34. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of 
immunotherapy with BRAF and MEK inhi bitors in BRAF(V600E) melanoma. Sci Transl 
Med. 2015;7(279):279ra241. 
35. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of 
pertuzumab in cancer patients base d on population pharmacokinetic analysis. Pharm Res. 
2006;23(6):1275-1284. 
36. Wang DD, Zhang S, Zhao H, Men AY, Pari var K. Fixed dosing versus body size-based 
dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 
2009;49(9):1012-1024. 
37. Zhang S, Shi R, Li C, Parivar K, Wang DD. Fixed dosing versus body size-based dosing 
of therapeutic peptides and proteins in adults. J Clin Pharmacol. 2012;52(1):18-28. 
38. Narwal R, Roskos LK, Robbie GJ. Populat ion pharm
acokinetics of sifalimumab, an 
investigational anti-interferon- α monoclonal antibody, in systemic lupus erythematosus. 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
84 Clin Pharmacokinet. 2013;52(11):1017-1027. 
39. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17-37. 
40. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. 
Myeloid cells obtained from the blood but  not from the tumor can suppress T-cell 
proliferation in patients with melanoma. Clin Cancer Res. 2012;18(19):5212-5223. 
 
DF/HCC Protocol #: 17-030  
Protocol Version Date: 31 July 2017 
 
85  
16. APPENDIX A PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity.  Fully active, able to carry on all pre-disease 
performance without restriction. 100 Normal, no complaints, no evidence 
of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease. 
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self, unable to carry on normal activity or to do active work.
2 In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. 60 Requires occasional assistance, but is able to care for most of his/her needs. 
50 Requires considerable  assistance and 
frequent medical care. 
3 In bed >50% of the time.  Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and assistance. 
30 Severely disabled, hospitalization indicated.  Death not imminent. 
4 100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospitalization indicated. Death not imminent. 
10 Moribund, fatal processes progressing rapidly. 
5 Dead. 0 Dead. 
          